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CHAPTER ONE 
INTRODUCTION AND OBJECTIVES 
The myelodysplastic syndromes [MOS] are clonal disorders of haematopoiesis 
characterized by an irreversible derangement in the development of the haematopoietic 
cell lines. They are currently thought to arise from mutational events in early stem cell 
development, (1,2,3,4) and it has been suggested that progression to acute leukaemia 
involves a further stem cell mutation (2,3,5). De novo acute leukaemia [AL] is a 
neoplastic proliferation of immature haemopoietic cells in the marrow which arises after 
the malignant transformation of a single haemopoietic stem cell (2,4,6). 
The diagnosis of MOS and acute non-lymphoblastic leukaemia [ANLL] is made by 
careful examination of blood films and bone marrow aspirates stained with appropriate 
dyes (2,4,6,7,8,9, 10, 11, 12). 
Because aspirates are diluted with sinusoidal blood, they may not accurately reflect the 
changes that are inherent in the myelodysplastic disorder and leukaemic process (13). 
On the other hand, a long core of marrow obtained by trephine biopsy provides a 
large volume of tissue, and overcomes the problems associated with aspiration due 
to markedly hypercellular infiltration or increased reticulin fibrosis (14, 15, 16, 17). In 
such a situation, trephine imprints may provide some limited information . 
Paraffin-embedded bone marrow trephines, which are the most widely used for 
diagnostic purposes, need to be decalcified prior to sectioning. This has a number 
of effects, and results in interference with the evaluation of the bone marrow 
(shrinkage, reduction in the quality of staining of the cells, and an impaired ability to 
apply the special stains used in marrow evaluation) (15, 18, 19). 
On the other hand, glycol methacrylate [GMA]-embedding of marrow cores, which 
obviates the need for decalcification, shows structural organization of the marrow, 
• 
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gives excellent cellular detail, and allows the application of cytochemical and 
immunocytochemical staining (13, 14,20,21,22,23,24,25,26). 
In order to document the extent to which the quantitative and qualitative morphological 
criteria proposed by the French-American-British [FAB] Cooperative Group could be 
applied directly to GMA-embedded marrow biopsy specimens, haematological studies 
were conducted on 13 newly diagnosed MOS patients and on 16 newly diagnosed 
ANLL patients. All cases were diagnosed and subsequently treated in the Department 
of Haematology at Groote Schuur Hospital. 
Further objectives were to assess the degree of diagnostic agreement between GMA-
embedded marrow biopsies and marrow smears, to establish whether cytochemistry 
and immunophenotyping could be applied to these sections and to assess if such 
techniques could be helpful in subdivision of MOS and ANLL. 
• 
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CHAPTER TWO 
LITERATURE REVIEW 
The diagnosis of ANLL and MOS is based primarily on the morphological and 
cytochemical characteristics of both the peripheral blood film and a sample of marrow 
obtained by aspiration. However aspirate samples are small, often selective and 
diluted with blood. As a result, some cell populations may not be represented in the 
aspirate smear but can be seen in the marrow biopsy sections (13). 
Cells which are firmly anchored within the marrow because of increased reticulin or 
those which are focally distributed may not be withdrawn on aspiration and thus may 
be excluded from examination (1, 13,27,28,29,30,31 ). 
One of the main advantages of bone marrow biopsy in haematological investigations 
is that it is possible to study haemopoietic cells in the marrow cavities 
(13,28,29,30,32,33,34) [Fig.1 ]. 
Figure 1: Normocellular marrow with well preserved marrow architecture and intact 
interface between marrow and bone. [H&Ex400) GMA 
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Normally, marrow erythroid precursors are present intertrabecularly in small clusters, 
in different stages of maturation. Early myeloid precursors are in proximity to the 
endosteal surfaces of trabeculae and to arterial vessels, whereas mature forms are 
scattered throughout the central intertrabecular areas. A distortion of this 
topographical distribution is found in several diseases, but typically in MOS 
(28,29,30,32). 
Differentiation of some cases of MOS and ANLL may be difficult in decalcified, paraffin-
embedded marrow biopsy specimens because of the reported inability to obtain 
reproducible blast counts, (31) and because a considerable percentage of cells cannot 
be easily recognized (34). 
In some reported studies, the aspirate was either inadequate or unsatisfactory in up 
to 30% of the cases in which a good trephine biopsy was obtained (31). Bone marrow 
cellularity, extent and homogeneity of the leukaemic infiltrate, as well as residual 
haemopoietic activity, were more accurately assessed in the sections than in the 
aspirate (13,28,31 ,34,35). 
Reports have recently been published of the use of myeloid markers in paraffin-
embedded specimens, but this still has very limited application, as only a few 
antibodies can be used (36, 18). 
• Hall et al (18) reported demonstrating of lymphoid antigens in decalcified bone marrow 
trephines, with some limited monoclonal antibodies. However, embedding marrow 
cores in glycol methacrylate [GMA] and obtaining 2 micron thick sections has 
improved the diagnostic information available from properly prepared bone marrow 
biopsy specimens. Aggregates of erythroid precursors, granulocytes at various stages 
of maturity, monocytes, macrophages, lymphocytes, and megakaryocytes are easily 
identified (13,34). 
In these sections, myeloblasts show a narrow rim of blue cytoplasm, a relatively round 
nucleus and a delicate chromatin pattern with one or more small nucleoli. 
• 
Figure 2: 
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GMA marrow section from a case of ANLL showing homogenous infiltration 
of the marrow with blasts. Mitotic figure can be seen. [H&Ex1000] GMA 
Monoblasts show abundant cytoplasm, a large irregular, convoluted nucleus, and 
delicate, sometimes lacy chromatin [Fig.3]. 
Figure 3: GMA marrow section from a case of acute myelomonocytlc leukaemia 
showing easily identifiable monocytic component [cells with irregular, 
invaginated nuclei] [H&Ex1000] GMA 
• 
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Promyelocytes and myelocytes are easily recognized [Fig.4]. 
Figure 4: GMA marrow section from a case of acute promyelocytic leukaemia [APL] 
showing infiltration of the marrow by promyelocytes. [H&Ex400] GMA 
Erythroblasts have a round nucleus, the chromatin has a granular appearance, and the 
cytoplasm is basophilic [Fig.5]. 
Figure 5: Prominent features of dyserythropoiesis in MDS - RAEB [multinuclearity, 
nuclear fragments] [H&Ex600] GMA 
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GLYCOL METHACRYLATE EMBEDDING 
Methacrylate resins {methyl and glycol methacrylate) have been used for many years, 
initially as embedments for ultrastructual studies in electron microscopy and recently 
as an alternative to paraffin wax embedding for a variety of tissues. 
Glycol methacrylate was introduced in 1960 as an embedding medium for electron 
microscopy by Rosenberg and used for undecalcified bone marrow embedding by 
Troyer and Nusbickel in 1975 who also noticed that this method resulted in 
preservation of marrow enzymatic activity {37). 
Resin embedding is superior to the paraffin method as it produces less tissue 
distortion, improves resolution of structural detail and if polymerisation occurs in the 
cold, there is significant reduction in protein denaturation. 
The main disadvantage of this method is the technical problems of achieving uniformity 
in section production, particularly with methyl methacrylate, as the specimen blocks 
tend to split and crack. The exothermic polymerization reaction has been another 
major problem, with the temperatures easily exceeding 100 OC, resulting in distortion 
of the tissue structure, protein denaturation and production of bubbles in the 
embedment. The main method of controlling the heat build-up in the tissue blocks has 
been the use of a water bath to dissipate the rapid rise in temperature. 
Alpha-terpinene, a heat moderator, has also been used to prevent excessive 
temperature rise during polymerisation {26). 
The ethylene glycol monester 2 - hydroxyethyl methacrylate may be formed by heating 
methacrylic acid and ethylene glycol. The produced monomer is a colourless liquid 
which is hygroscopic, this being a major advantage as this may be used as a 
dehydrating agent instead of ethanol or acetones. 
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As with other methacrylates, the GMA is usually mixed with a variety of plasticizers and 
initiators which improve the cutting properties of the block as well as ensuring 
reproducible polymerization. 
Polyethylene glycol modifies the hardness of the block, while butoxyethanol and N,N 
- dimethylaniline act as softners and initiators. Induction of the polymerization process 
takes place by either heat or ultraviolet light provided that benzoyl peroxide is present 
as a catalyst. (37) 
Due to the density of bone specimens, it is necessary to apply vacuum infiltration in 
order to obtain an even methacrylate penetration in these tissues. 
Once polymerized, the blocks may be stored almost indefinitely at room temperature, 
but cold storage at -20 OC is mandatory if cytochemistry or immunophenotyping is 
intended. 
Conventional microtomes used to cut sections from paraffin blocks are not suitable to 
cut 2 micron thick sections from GMA blocks, which thus requires the use of specially 
hardened knives, for example, tungsten knives. 
Sections are attached to clean glass surfaces by drying at room temperature without 
the use of special adhesives. 
In recent years, several studies have been published with the use of GMA as an 
embedding medium for marrow biopsies for the diagnosis and classification of 
haematological malignancies. (13,28,29,30) 
9 
THE MYELODYSPLASTIC SYNDROMES [MDS] 
During the last 40 years haematologists have observed that some of their patients with 
ANLL had had pre-existing morphological haematological abnormalities which had 
antedated the diagnosis of leukaemia by months or even years. 
These individuals were reported to have had peripheral blood cytopenias. While the 
marrow was usually hypercellular, the blast count was less than 5%, and there were 
obvious signs of maturation abnormalities in one or all three haemopoietic lines. 
As a result of the introduction of iron stains on bone marrow smears, several cases of 
sideroblastic anaemia were diagnosed in the 1960's, but refractory anaemia and 
smouldering· leukaemia were not recognized at that time (5). 
However, a retrospective study of bone marrows performed then showed that there 
had been a significant number of megaloblastic and dyserythropoietic marrows which 
were resistant to both folate and Vit B12 therapy, and it was agreed that these would 
be labelled MOS (5). 
At present, the number of newly diagnosed MOS cases is increasing every year. In 
the United States the incidence of MOS diagnosis is estimated at about one new case 
for 100 000 persons per year (38). 
Myelodysplastic conditions may be either congenital or acquired. The latter can be 
further divided into primary and secondary MOS (5). 
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PATHOGENESIS 
The current concept of the MOS's is that they represent the early phase of an acute 
nonlymphoid (most frequently) leukaemia [ANLL] with a slowly proliferating clone. This 
clone, which replaces normal haemopoietic cells and is characterized by ineffective and 
dysplastic haemopoiesis, most commonly results in a hypercellular marrow and 
peripheral blood cytopenia (1,2,4,5,30,39,40,41,42,43,44). The marrow is hypocellular 
in only about 10% of all cases ( 41 ,44). The defect may be principally manifested in 
one lineage, but is more commonly bilineal or trilineal. It appears that the abnormal 
clone has a growth advantage over normal haemopoietic stem cells and will 
progressively replace them (5,45). These abnormal progeny can be shown by 
karyotypic analysis to be clonal in origin, particularly in secondary MOS (2,5). 
A schematic representation of the developmental pathway for haemopoietic cells is 
shown in Table 1. MOS and AL represent clonal disorders which are currently thought 
to arise from mutation in an early stem cell, evolving to ALL or ANLL. 
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Table 1: 
Pluripotential stem cells 
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0~ -----o----@ ~~~r~c:~=~e 
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:-:-: P late iets 
I ICAU-Mk) 
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Lymphoid, lcFu-sJ 
SC ', 0------'----/a\ ~ B lymphocyte 
0,~ 
'..._/ --;--__I O' _______ la\ 
• T lymphocyte 
I 
Abbreviations: 
PHSC, pluripotential haemopoietic stem cell; SC, stem cell; CFU-GEMM, 
colony-forming unit, granulocytic-erythroid-macrophagic-megakaryocytic; BFU-E, 
burst-forming unit, erythroid; CFU-E, colony forming unit, erythroid; CFU-GM, 
colony-forming unit, granulocyte-macrophage; CFU-Eo, colony-forming unit, 
eosinophilic; CFU-Mk, colony-forming unit, megakaryocytic; CFU-8, colony-forming 
unit, 8 lineage; CFU-T, colony-forming unit, T lineage (2). 
The most common type of MOS is primary MOS in which more than 90% of patients 
are over 40 years of age with more than 50% being over 70 years (5). According to 
a recently published study the annual incidence of MOS in children less than 15 years 
is 3.4/1 000 000 ( 46). 
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In secondary MOS patients, there is often a history of cytotoxic drugs use and/or 
radiotherapy for malignant or non-malignant conditions (2,5). The agents responsible 
for secondary MOS include alkylating agents - melphalan, chlorambucil, treosulphan, 
procarbazine, cyclophosphamide, busulphan, razoxane, and the nitrosureas, which 
produce profound and prolonged cytopenia (2,5). 
The risk of developing secondary MOS increases with age_ and the past duration of 
exposure to drugs or radiotherapy. It can reach 15-20% after 10 years (5). Congenital 
MOS has been recently described, but is believed to be extremely rare (47). 
CLINICAL FEATURES 
MOS is characterized by a very slow progression, and is often discovered incidentally 
during investigation for other reasons (2,4). Pallor associated with anaemia is often 
present. Patients with even a very low haemoglobin concentration [60-80 g/L] have 
relatively mild symptoms - weakness and exertional dyspnea, which suggests that 
there has been adaptation over a long period of time. Some individuals may present 
with infection due to neutropenia, or with bleeding due to thrombocytopenia and 
platelet dysfunction. 
Clinical examination may reveal a palpable spleen, a sign more likely to be found in 
chronic myelomonocytic leukaemia [CMML] (2). Hepatomegaly occurs only in about 
5% of MOS patients (4). 
MORPHOLOGICAL ABNORMALITIES 
In 1982 the French-American-British [FAS] Cooperative Group proposed a 
morphological classification of the myelodysplastic syndromes, (9) and this has since 
been widely adopted. 
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The abnormalities of the erythroid, granulocytic and megakaryocytic series are 
assessed in well-prepared peripheral blood and bone marrow films stained with 
Romanowsky dyes such as the May-Grunewald-Giemsa stain. 
The FAS group proposed that MDS's be defined by the following. 
Dyserythropoiesis: 
Peripheral blood abnormalities are primarily seen as changes to the red blood cell 
[RSC] morphology [macrocytes, dimorphism, polychromatic cells, punctate basophilia 
and, rarely, the presence of nucleated RSC] which is often an indication to look for 
dyserythropoiesis in the bone marrow. It is believed that these abnormalities are 
primarily a result of disordered erythropoiesis. Anaemia is an almost universal 
quantitative abnormality of the erythroid series, and is usually the result of ineffective 
erythropoiesis. This can be demonstrated by ferrokinetic studies. Quantitative 
abnormalities of the bone marrow which may reflect extreme defects in RSC 
production include the presence of more than 15% ring sideroblasts, and the 
nucleated bone marrow cells having either a greater (more than 60%) or a smaller than 
usual (less than 5%) proportion of erythroid precursors. Qualitative abnormalities in 
the bone marrow include the presence of ringed sideroblasts, multinuclearity, nuclear 
fragments of various sizes, abnormal nuclear shape (e.g. single, double or triple 
indentations resulting in two or more nuclear lobes of equal or unequal size or an 
• irregular outline) [Fig.5] and abnormal cytoplasmic features (e.g. irregularities in the 
density of staining which, when extreme, shows as clear unstained areas with ill-
defined edges that occupy a variable proportion of the cytoplasm and punctate 
basophilia) (9) . 
Dysgranulopoiesis: 
Morphological abnormalities in granulocytes may be seen in the peripheral blood and 
the bone marrow. In the peripheral blood the neutrophils may appear as agranular or 
hypogranular on May-Grunwald-Giemsa stain. In some cases the cytoplasmic 
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abnormalities are represented by the persistence of basophilia in mature cells. 
Abnormalities in the nuclear segmentation may be seen as hyposegmentation (Pelger-
Huet-like anomaly) [Fig.6] or hypersegmentation with bizarre shapes (9,48). 
Figure 6: Presence of ALIP and pseudo Pelgar - Huet forms in MDS - RAEB - t case. 
[H&E x600] GMA 
In the bone marrow, abnormal staining of the primary (azurophilic) granules is one of 
the major abnormalities found in the promyelocytes and myelocytes. In some cases 
the cells seem to be devoid of granules while in others the primary granules appear 
larger than normal. In the bone marrow the secondary granules may be absent or 
reduced in the myelocytes and later forms including mature granulocytes (9). In 
addition, there may be irregular distribution of the cytoplasmic basophilia, with a dense 
rim of basophilia in the periphery of the cells, and a lack of it in the perinuclear area. 
The same nuclear abnormalities of the mature granulocytes that are seen in the 
peripheral blood are also present in the bone marrow (9). 
• 
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Oysmegakaryocytopoiesis: 
Peripheral blood may show the presence of giant platelets, or, rarely, megakaryocyte 
fragments. Qualitative abnormalities in the marrow are frequently found and 
sometimes there is a reduction in the number of megakaryocytes as the result of a 
quantitative defect being also present. Qualitative abnormalities include 
micromegakaryocytes, [Fig.7] large mononuclear forms and cells with multiple small 
separated nuclei. Occasionally megakaryocytes with giant and/or abnormal granules 
are seen. Varying proportions of these abnormal forms and of normal 
megakaryocytes are found (9,27,49). 
Figure 7: Oysplastic megakaryocytes [micromegakaryocytes] in MOS - RAEB. 
[H&E x600] GMA 
Blast cells seen in MOS: 
Type I blasts vary from cells which are indistinguishable from myeloblasts to cells of 
various size which may be unclassifiable. Cytoplasmic granules are always absent and 
they usually have prominent nucleoli and an uncondensed chromatin pattern. The 
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nuclear/cytoplasmic ratio of the smaller blasts tends to be higher than that of the larger 
ones (9). 
Type II blasts have a few primary (azurophilic) granules. Otherwise, they resemble 
type I blasts except that the nuclear/cytoplasmic ratio tends to be lower and the 
nucleus remains in a central position (9). 
If the following characteristics are present, the cells should no longer be considered 
to be type II blasts and should be classified as promyelocytes - cells with eccentric 
nucleus and developed Golgi apparatus (seen as a clear zone in the vicinity of the 
nucleus), with a denser and/or clumped chromatin pattern, and with numerous 
granules and a low N/C ratio. Deficiency of primary granules or their failure to take up 
the stain may result in a hypogranular or agranular promyelocyte which can be 
recognized by the remaining four features (9). 
The FAB classification of the myelodysplastic syndromes can be summarized as shown 
in Table 2. 
Table 2: The FAB morphological classification of the Myelodysplastic Syndromes 
Category Blood 
1. Refractory anaemia [RA] < 1 % blasts 
2. RA with ring sideroblasts < 1 % blasts 
[RARS] 
3. RA with excess of blasts < 5% blasts 
[RAES] 
4. RAES in transformation 
[RAES-t] 
>5% blasts 
Bone marrow 
<5% blasts 
< 15% RS [ring sideroblasts] 
<5% blasts 
>15% RS 
5-20% blasts 
21-29% blasts 
5. Chronic myelomonocytic 
leukaemia [CMML] 
<5% blasts <20% blasts. Excess of 
> 1 x 1 o9 monocytes monocyte precursors 
The diagnosis is RAES-t if Auer rods are present in bone marrow or peripheral blood 
blasts (9). 
• 
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CYTOGENETIC ABNORMALITIES 
Karyotypic abnormalities in the haemopoietic cells have been reported in about half the 
MOS patients (2,4,39,50,51,52,53,54). Interestingly, the chromosomes most frequently 
involved carry genes important for haemopoiesis, e.g. chromosomes 5 and 7, which 
contain genes for haemopoietic growth factors and its receptors, and for erythropoietin 
respectively. 
Recently, several haemopoietic growth factors [GM-CSF, M-CSF, 11-3,11-4, 11-5] as ~ell 
as the c-fms proto-oncogene, were located on the distal arm of chromosome 5 (6,55). 
The most common cytogenetic anomalies in MOS involve chromosome 8, [ +8 or 
trisomy 8]. chromosome 7, [-7 or monosomy 7] and chromosome 5 [-5 and Sq- or 
interstitial deletion of part of the long arm of chromosome 5 (2,5,6,50). 
Chromosome 8 carries the c-myc oncogene, and the portion of chromosome 5 which 
is frequently lost in MOS and ANLL corresponds to the c-fms oncogene. Amplification 
of the c-myc oncogene has been reported in blastic crisis of chronic myeloid 
leukaemia [CML] and in ANLL (6,53). On the normal chromosome, c-myc oncogene 
is transcriptionally silent. The relocation of c-myc leads to the persistent activation of 
this gene and may play a key role in cell transformation (54). 
Involvement of chromosomes 5 and 7 is prominent in secondary MOS but, in contrast 
to primary MOS, chromosome 8 remains unaffected (5). The presence of the -7 
chromosomal abnormality predicts a higher incidence of transformation to overt ANLL 
than do abnormalities of chromosome 5 (6). 
Chromosome patterns which are not seen in MOS are t[8;21] and t[15;17]. 
Karyotype anomalies are useful confirmatory evidence for an MOS clone, and can 
confirm a doubtful diagnosis in some patients. 
Chromosomal abnormalities associated with MOS are listed in Table 3. 
• 
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Table 3: 
Category Cytogenetic abnormalities 
---------------------------------------------------------------------------------1. Refractory anaemia. [RA] Sq-, +8, -7 
----------------------------------------------------------------------------------------------2. RA with ring sideroblasts. [RARS] Sq-, +8, -7 
20q-, 11q-
----------------------------------------------------------------------------------------------3. RA with excess of blasts. [RAES] 
4. RAES in transformation. [RAEB-t] 
5. Chronic myelomonocytic leukaemia. 
[CMML] 
FUNCTIONAL ABNORMALITIES 
Sq-, +8, -7, -5 
Sq-, +8, -7, -5 
-7, +8, 12p-
Various defects in red cells, granulocytes and platelets in MOS have been described 
(2,5,6,44) They include altered function of glycolytic enzymes in red cells [pyruvate 
kinase deficiency], increased concentration of Hb-F [80% of patients with MOS], and 
altered expression of blood group antigens. 
Other enzyme activities like hexokinase and glucose-6-phosphate dehydrogenase 
frequently exhibit increased activity (5). 
Granulocyte abnormalities include defective adhesion, orientation, aggregation, 
chemotaxis, phagocytosis, degranulation, decreased myeloperoxidase content, release 
and killing capacity against bacteria and yeasts (2,5,44,56) . 
However, granulocyte function in patients with RARS did not differ from normal 
controls, implying that these individuals may form a separate entity (5). Lymphocytes 
were found to have decreased DNA-repair potential, while alterations in natural killer 
cell activity were also reported (56}. 
Platelet abnormalities include defective aggregation, adhesion to glass, and reduced 
thromboxane Az activity (2). The platelet count remains the most important factor in 
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the prediction of a bleeding tendency, and there have been only a few reports of 
haemorrhage and thrombosis due to abnormal platelet function (2,4,5). 
PROGNOSIS 
Problems related to cytopenia limit survival in patients with MOS. Anaemia and 
transfusion-related problems, agranulocytosis and thrombocytopenia are more frequent 
causes of death than is a transformation to ANLL. 
The median duration of survival in large studies varies according to the morphologic 
subclass, being 76 months for RARS, 32 months for RA, 10,5 months for RAEB, and 
only 5 months for RAEB-t (2). The median survival for CMML is 38 months (2) [see 
Table 4]. 
Table 4: 
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(2) (Mufti et al) 
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The bone marrow blast cell count is the single most important determinant of the 
prognosis - the duration of survival being markedly worse when the blast-cell count is 
greater than 5%, (32,57,58,59) but, in a recently published study, White et al (51) 
showed that karyotype status is also an important prognostic indicator, not only in 
relation to survival, but also to the risk of leukaemic transformation. 
Secondary MOS carries a very poor prognosis with a disappointing response to 
treatment and short survival times because of its faster evolution to acute leukaemia 
(58). 
De Wolf-Peeters et al (30) reported that the abnormal localization of immature cells 
[ALIP] predisposes MOS patients to a progression to overt AML. 
ALIP is defined as being the presence of abnormally located myelopoiesis, clustering 
centrally in the marrow with a shift to more immature forms - namely myeloblasts and 
promyelocytes (1) [Fig.6]. 
The absence of ALIP seems to carry a better prognosis, but this bears no relation to 
morbidity and mortality as a result of other complications such as infections (6). 
Gosson et al (60) stressed that there was a significantly worse prognosis for ANLL 
patients with trilineage myelodysplasia, and that many of these patients probably 
progressed from RAEB-t to overt ANLL. 
TREATMENT 
Results of treatment of MOS patients are often disappointing. Adequate symptomatic 
treatment is important, but red cell transfusion should be limited to patients with 
symptoms of anaemia, as some of them, in the long term, may develop iron overload 
as a result of frequent blood transfusions. 
• 
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Prompt treatment with the appropriate antibiotics is warranted in neutropenic patients, 
as they are susceptible to infections that can be lethal (2,6). Platelet transfusions are 
given when bleeding is a problem, or in the case of extreme thrombocytopenia. 
Patients with splenomegaly may develop hypersplenism requiring splenectomy (2). 
RARS and RA both have a relatively good prognosis in the short term and are 
managed conservatively with supportive therapy - blood and platelet transfusions 
(2,5,39,43,61,62,63). 
At present therapeutic regimens for the high-grade MOS are under investigati~n 
(2,4,5,39,43,61). These involve the use of putative stem-cell differentiating agents, such 
as cytosine arabinoside [ara-C] at low dosage, generally with 10-20% of individuals 
achieving complete remission. 
However, the durability of these responses was usually short and no improvement in 
survival was noted. In younger patients, marrow ablative treatment followed by 
allogenic bone marrow transplantation has been reported in recent studies to achieve 
45% disease-free survival for three years, with 23% having a probability of relapse (61). 
This treatment is usually restricted to patients below the age of 40 who have a 
histocompatible bone marrow donor. However, the majority of MOS patients are 
above this age, and therefore are not appropriate candidates for bone marrow 
transplantation (2,5) . 
Recently, the use of haemopoietic growth factors - granulocyte colony-stimulating 
factor, [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], and 
interleukin-3 [11-3] - have been shown to improve the neutrophil counts and marrow 
morphology in a high proportion of patients, and for G-and GM-CSF these responses, 
although initially present, were short lived. In some subjects a decrease in red cell 
transfusion requirements occurred, blood leucocyte counts increased significantly, 
whereas platelet counts remained unchanged (6). Thus, haemopoietic growth factors 
provide encouraging alternatives to chemotherapy or bone marrow transplantation for 
• 
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elderly patients, as they improve marrow recovery, although the effect is limited to the 
period of administration of the agent. 
EVOLUTION OF MDS 
Patients with MOS may die of marrow failure as a direct consequence of disease, or 
following transformation to acute leukaemia, which may develop within a short time or 
evolve in a stepwise fashion over many weeks, month or even years. 
Myelodysplastic syndromes may also progress into other usually less favourable 
categories. Thus RA and RARS may evolve into either CMML or RAES, both of which 
may in turn progress to RAES-t {6,59). Patients with RAES and RAES-t show a high 
incidence of evolution to ANLL - 42% and 59% respectively - in contrast to RA and 
RARS cases with 12,5% and 11,5% respectively {60). The acute leukaemia which 
occurs in MOS is almost always ANLL, but rare cases of ALL and of bilineage / 
biphenotypic leukaemia have been reported (6). Since MOS is a disease of the elderly, 
a significant proportion of patients with MOS succumb to other diseases. 
ACUTE LEUKAEMIA [AL] 
Acute leukaemia [AL] is a malignant proliferation of immature haemopoietic cells in the 
bone marrow which arises as a result of somatic mutation of a single haemopoietic 
stem cell {2,6). Leukaemia is probably a multiple-step process that requires the altered 
expression of several interrelated genes in the same cells. Myeloid leukaemia arises 
in multipotent stem cells that are capable of differentiating into cells of myeloid, 
erythroid, monocytic, and megakaryocytic lineages (2,6). The leukaemic blast cells 
accumulate in the marrow and suppress the proliferation and differentiation of normal 
haemopoietic cells, leading to diminished production of erythrocytes, granulocytes and 
platelets. 
.. 
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Acute leukaemias are divided into two major groups - acute non-lymphoblastic 
leukaemia [ANLL]. and acute lymphoblastic leukaemia [ALL]. 
In addition, hybrid acute leukaemias have recently been recognized in which leukaemic 
cells express markers of two lineages (4,64,65,66,67). When more than 10% of 
malignant cells in a hybrid leukaemia demonstrate both lymphoid and myeloid features, 
the leukaemia is termed biphenotypic. However, if the leukaemic cells are 
heterogeneous with single cells displaying either lymphoid or myeloid features but not 
both, the leukaemia is termed bilineal or biclonal. 
AETIOLOGY 
The cause of acute leukaemia in humans is not known. Several factors may play a 
role in the induction of certain types of leukaemia, including the following: 
1. Environmental agents: 
• ionizing radiation: 
The leukaemogenic potential of ionizing radiation has been known for 
years. It increases with the amount, quality and time of exposure 
(2,4,68) . 
• viruses [retroviruses]: 
Retroviruses carry oncogenes that are caused by the transduction of 
genes [proto-oncogenes] of vertebrate cells. The growth of cells is 
critically regulated by proto-oncogenes: others code for growth factors, 
such as platelet derived growth factor, encoded by c-sis; others code for 
the receptors of growth factors, such as the receptor for macrophage 
colony- stimulating factor, encoded by c-fms; some code for transducers 
within the cell that help ramify a cell surface signal, such as ras 
oncogenes (2,4,6,9,). 
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ANLL appears to exhibit the highest frequency of ras oncogene 
activation of any human tumour so far studied (6,69). To date, oncogene 
analysis does not play a role in the diagnosis of acute leukaemia. 
However, since leukaemogenesis is a multistep process in which proto-
oncogenes are activated by point mutation, truncations, chromosomal 
translocations, and/or over- or under-expression, oncogenic expression 
at numerous molecular levels may become more important in diagnosis. 
• chemical carcinogens [benzene]: 
The incidence of acute leukaemia in workers exposed to benzene is two 
to ten times greater than in the general population ((2,4,70,71,72). 
• alkylating agents [melphalan, busulphan, chlorambucil]: 
The combination of irradiation and alkylating agents has resulted in a 
higher incidence of 11secondary11 leukaemias with the time between the 
original malignant diagnosis and the development of bone marrow 
haematological malignancy being between 3 and 5 years (2,4,5,73,74). 
Patients developing ANLL include those with Hodgkin's and non-
Hodgkin's lymphoma, multiple myeloma, hairy cell leukaemia, and 
various solid tumours. These leukaemias have also been shown to be 
associated with a high incidence of chromosomal abnormalities involving 
chromosomes 5 and 7 (2). 
2. Genetic condition: 
Individuals with hereditary disorders such as Down's syndrome, Bloom's 
syndrome, Fanconi's anaemia, ataxia telangiectasia, and congenital 
agammalobulinemia are prone to develop acute leukaemia. Down's syndrome 
is associated with stable trisomy 21, whereas Bloom's syndrome, Fanconi's 
anaemia, and ataxia telangiectasia are autosomal recessive disorders which are 
• 
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associated with multiple chromosomal breaks, aberration, and 
endoreduplication in cultured cells (2,4,6). 
Acquired diseases: 
Pre-existing conditions such as myelodysplastic syndromes, aplastic anaemia, 
multiple myeloma, and paroxysmal nocturnal haemoglobinuria {2,4). 
CLINICAL PRESENTATION 
ANLL has a low incidence in childhood, less than 1 case/100 000/year, and incidence 
rises with age from 1/100 000/year in the fourth decade to approximately 10/100 
000/year in those over 70 (38). 
Patients present with nonspecific systemic manifestations, such as fatigue.weight loss, 
fever or bruising. As a result of marrow infiltration, the patient develops anaemia, 
leucopenia and thrombocytopenia which lead to prostration, severe infections and 
bleeding. 
Thrombocytopenic patients present with a history of easy bruising, petechiae, epistaxis, 
gingival bleeding and prolonged bleeding after injuries. Bleeding may occur from any 
site, and haemorrhages potentially fatal are intracranial, gastrointestinal and pulmonary. 
Less common symptoms of acute leukaemia include retinal haemorrhages and the 
development of extranodal masses in the subcutaneous tissues, orbits, breasts, or 
testes (4). 
Some patients develop persistent or recurrent skeletal pain or tenderness, such as 
sternal pain or swelling of the large joints {2,4). Leukaemic patients may have organ 
infiltration (eg. liver, lymph nodes or brain), this being more common in ALL Infiltration 
of the gingivae and skin is fairly common in myelomonocytic and monocytic ANLL 
Meningeal leukaemia occurs in ANLL in only about 5% of adults as compared to 70% 
of those with ALL 
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The most serious and life-threatening complication of leukaemia is infection which 
develops as a result of the breakdown of normal defence mechanisms. Natural 
barriers to infection, adequate inflammatory responses, and cellular and humoral 
immunity are all disrupted by leukaemia. The risk of infection is particularly high when 
the granulocyte count decreases to below 0,5 x1 o9 /L. 
Pyogenic infections of the skin are most common, with major infections such as 
sinusitis, pneumonia, pyelonephritis and meningitis being rare as presenting features. 
Leukaemic therapy itself injures the gastrointestinal mucosa, creating a portal of entry 
for microorganisms. Venipunctures, marrow aspirations an,d biopsies and bladder 
catheterizations result in local injury which may lead to serious infection (4). 
DIAGNOSIS 
At present the differentiation and classification of AL not only requires simple 
morphological and cytochemical evaluation, but, in some cases, it is also necessary 
to use monoclonal antibodies, electron microscopy or molecular biological techniques 
such as gene rearrangement studies (2, 4, 6, 7, 8, 10, 11, 12, 20, 36, 38, 64, 65, 66, 
75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 ,90, 91, 92, 94). 
• In 1976 the FAB Cooperative Group published proposals for the morphological 
classification of the acute leukaemias, (8) which have been widely adopted and used. 
These proposals were revised by the FAB Cooperative Group in 1985, (11) and criteria 
for M7 were added (10). In 1991 criteria for MO (7) were added. 
The presence of more than 30% of type I or type II blasts in the marrow is diagnostic 
of acute leukaemia (8, 11 ). 
• 
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The FAB morphological classification of ANLL (7,8, 10, 11, 12) 
1. MO Undifferentiated myeloblastic 
2. M1 Myeloblastic without maturation 
3. M2 Myeloblastic with maturation 
4. M3 Promyelocytic 
M3V Promyelocytic - variant 
5. M4 Myelomonocytic, with both granulocytic and monocytic differentiation 
M4E Myelomonocytic, with eosinophilia 
6. M5 Monocytic 
M5a - Monoblastic 
M5b - Monocytic 
7. M6 Erythroleukaemia [with >50% erythroblasts and >30% of nonerythroid 
cells being blasts] 
8. M7 Megakaryoblastic 
MO - cannot be diagnosed on morphological grounds alone as the blasts are 
large and agranular. They should be identified by the following features: 
negative myeloperoxidase and Sudan Black B reaction [ or positivity in 
less than 3% of blasts], negative B and T lineage markers, and 
expression of myeloid antigens recognized by at least one monoclonal 
antibody, either CD 13 or CD 33 . 
Other myeloid markers are often also positive, and these include CD 11 b 
and the enzyme myeloperoxidase [MPO] demonstrated by 
immunocytochemistry and/or electron microscopy analysis (7). 
M1 - the sum of blast cell types I and II must be 90% or more of all the 
nonerythroid cells with at least 3% of the blasts being myeloperoxidase 
or Sudan Black B positive and a varying proportion of blasts containing 
at least a few azurophilic granules, Auer rods or both (8, 11). 
.. 
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M2 - the sum of blast cell type I and II is between 30% and 89% of the 
nonerythroid cells. Monocytic cells make up less than 20% of the total 
and maturation at or beyond the promyelocyte stage is present in more 
than 1 0% of the bone marrow cells. 
The leukaemic cells are often nucleolated and have varying amounts of 
cytoplasm, usually with many azurophilic granules. Cells containing Auer 
rods, almost always single, are common {8,11). 
M3 - the great majority of cells are abnormal promyelocytes, with a 
characteristic pattern of granulation, and with bundles of Auer rods 
almost invariably being present in some of the cells in the peripheral 
blood and marrow. Promyelocytes nuclei vary greatly in size and shape 
and are often reniform or bilobed {8, 11 , 12). 
M3 variant - is characterized by a cell with a reniform, bilobed, multilobed or 
convoluted nucleus and with either sparse fine granules or agranular 
cytoplasm. 
A variable proportion of cells may have multiple Auer rods, fine dust - like 
granules, or large oval or elliptiform cytoplasmic inclusions with the same 
staining characteristic as primary granules. Typical hypergranular 
promyelocytes constitute a small minority of the leukaemic cells in 
peripheral blood. They are usually more numerous in the bone marrow. 
The white count is usually considerably higher in M3 variant than in M3 
(38). 
M4 - the diagnosis of M4, and its separation from M2 and M5, require 
assessment of both the peripheral blood and the bone marrow films. In 
bone marrow, the blast cells account for more than 30% of the 
nonerythroid cells. The sum of myeloblasts, promyelocytes, myelocytes, 
and later granulocytes is 30% or more but less than 80% of the 
• 
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nonerythroid cells. More than 20% of the nonerythroid cells are cells of 
the monocytic lineage at different stages of maturation; usually they are 
promonocytes and monocytes. When the monocytic cells exceed 80%, 
the diagnosis is M5 (monocytic leukaemia.) 
When the bone marrow findings are as above, and the peripheral blood 
monocyte count (monoblasts, promonocytes, monocytes) is 5 x109 /Lor 
more, the diagnosis is M4. 
.. 
If the monocyte count is less than 5 x1 o9 /L, a diagnosis of M4 can still 
be made if the bone marrow findings are as described above, and the 
presence of a significant monocytic component has been confirmed by 
ancillary laboratory tests, such as serum lysozyme estimations, or by 
cytochemical methods that incorporate either a double esterase reaction, 
specific chloroacetate esterase and non-specific alpha-naphthyl acetate 
esterase, or other esterase stains that identify monocytes, such as 
naphthol ASD acetate, with and without incubation with sodium fluoride. 
The diagnosis of M4 is established if more than 20% of the bone marrow 
precursors are monocytes, as shown by cytochemical reactions, or if the 
lysozyme concentrations exceed three times the normal values in serum 
(11.54 µ.g/mL), urine (2.5 µ.g/mL), or the reference values in individual 
laboratories. If the bone marrow resembles that of cases of M2, a 
diagnosis of M4 is still possible if the peripheral blood monocyte count 
is 5 x 109 /L or more and one of the above tests provides evidence for 
an increased monocytic component in the bone marrow (8, 11). 
M4 - with eosinophilia [M4E] 
In a small percentage of cases of M4, eosinophils are present in the 
bone marrow; they usually amount to 5% or more of nonerythroid cells. 
These eosinophils are abnormal, and some have large basophilic 
(immature) granules, in addition to the characteristic specific eosinophilic 
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Figure 8: 
granules, and may have a single unsegmented nucleus. In contrast to 
normal eosinophils, these cells have cytochemical reactions to 
chloroacetate esterase [Fig. 8] and periodic acid Schiff that are distinctly 
positive. 
Chloroacetate esterase positivity in coarse granules of abnormal 
eosinophils in a case of M4E. [x600] GMA 
The FAS Cooperative Group proposed that such cases be designated 
as "M4 with eosinophilia". Although cells with these features can rarely 
be identified in cases of M2, the cases with M2 and bone marrow 
eosinophilia generally lack the abnormal eosinophil granules seen in M4 
with eosinophilia (8, 11 ). 
MS - the diagnosis of MS is based on the appearance of the bone marrow. 
One criterion suffices: if 80% or more of all the nonerythroid cells in the 
bone marrow are monoblasts, promonocytes, or monocytes. The 
definitions of the two subtypes MSa and MSb are modified as follows: for 
MSa, 80% or more of all the monocytic cells are monoblasts; and for 
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M5b, less than 80% of all the monocytic cells are monoblasts, the 
remainder being promonocytes and monocytes (8, 11). 
M6 - to avoid confusing M6 with other megaloblastic and dyserythropoeitic 
states, the FAB group specified that more than 30% of all the bone 
marrow cells had to be myeloblasts or promyelocytes. Using this 
criterion, the FAB group have since recognized that in some cases of 
M6, in which a high proportion of the erythroblasts were bizarre cells, the 
erythroid component was so large that it was impossible to diagnose M6 
.. 
from the original FAB definition as the blast cells accounted for less than 
30% of all nucleated cells of the bone marrow. 
They revised the criteria for the diagnosis of M6 by requiring that 30% or 
more of the remaining nonerythroid cells be type I or type II blast cells. 
The proposed criteria for the diagnosis of M6 are thus different from 
those used for the other subtypes of acute myeloid leukaemia (M1-M5). 
Subtype M6 can now be diagnosed when less than 30% of all nucleated 
cells of the bone marrow are blast cells; some of these cases would 
previously have been classified as refractory anaemia with excess blast 
cells (RAES) or with excess blast cells in transformation (RAEB-t) with a 
major erythroid component. When 50% or more of all nucleated cells are 
erythroblasts, the diagnosis becomes myelodysplastic syndrome if less 
• than 30% of the nonerythroid cells are blast cells (8, 11). 
M7 - leukaemic megakaryoblasts are frequently highly pleomorphic (10). 
Prominent and multiple nucleoli and cytoplasmic basophilia have been 
noted. There is some heterogeneity in cell size with approximately 20-
30% of the blasts being two or three times larger than normal 
lymphocytes. At times, cells in either the bone marrow or peripheral 
blood may have cytoplasmic blebs. The nature of megakaryoblasts may 
be suggested by the pattern of cytoplasmic reactions - they do not stain 
with Sudan Black B or peroxidase, are almost always negative for alpha-
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naphthyl butyrate esterase, [ANBE] and are frequently PAS and acid 
phosphatase positive with a localized pattern. 
The ultrastructural examination may show that a positive peroxidase 
activity in megakaryoblasts is localized exclusively on the nuclear 
membrane and the endoplasmic reticulum, whereas in myeloblasts the 
reaction occurs in the Golgi area and cytoplasmic granules. 
The use of immunological techniques may demonstrate positive reactions 
for factor VIII-related antigen, platelet factor 4, platelet derived growth 
factor and platelet membrane glycoproteins. 
Myelofibrosis or increased bone marrow reticulin are prominent aspects 
in most patients with M7 (1 O). 
CYTOCHEMISTRY 
The rationale for the use of enzyme and immunologic markers in the classification of 
malignancies is that during differentiation each cell line normally synthesizes particular 
chemical substances that enable the cells to perform their unique functional role when 
they mature and are fully differentiated (94,95,96). Many of these substances are 
unique to one cell line, and may appear at a specific stage of maturation. If leukaemic 
cells can be shown to contain such substances, they can be considered by analogy 
with normal cells to be of a particular cell lineage. 
Four types of cytochemical stains were found to be essential for the diagnosis and 
precise classification of ANLL: 
1 . Myeloperoxidase [MPO] - which is formed very early in normal cells committed 
to nonlymphoid maturation and has never been reported in lymphoid cells (22). 
Myeloperoxidase activity is found in primary granules of the granulocytic series 
.. 
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and lysosomal granules of the monocytic series. It is found in cell lines 
developing into neutrophils, eosinophils, basophils, and monocytes (95,96). 
Myeloblasts may or may not stain with myeloperoxidase at the light microscopic 
level, but they may stain the perinuclear cisternae and endoplasmic reticulum 
prior to packaging into granules at the electron microscopy level. 
2. The monocyte has ectoenzymes that readily hydrolyses alpha-naphthyl acetate 
esterase [ANAE], alpha-naphthyl butyrate esterase [ANBE], or the naphthol-AS 
acetate esterase [NASA] at acid pH, which gives a characteristically strong 
diffuse reaction in monocytic leukaemias, M4 or MS. All these esterase 
reactions are sensitive to inhibition by sodium fluoride (22,96). Granulocytes 
and lymphocytes are usually negative for ANAE and ANBE, but helper T-cells 
show dense localized dotlike positivity with ANAE. 
The monocytic leukaemias [MS] are defined by the presence of diffuse ANBE 
and the absence of naphthol-AS chloracetate esterase [CAE]; peroxidase may 
or may not be present (2,6,22,70). 
3. Naphthol-AS chloracetate esterase is reported to be useful in the diagnosis of 
myeloblastic leukaemias and, in cases in which peroxidase is negative, can be 
used on its own for diagnosis. Chloroacetate esterase is positive in myeloid 
haemopoietic cells, and has also been found to be positive in abnormal 
eosinophils of M4E and mast cells (22,32,64,96). 
The myeloid leukaemias are thus defined by the presence of peroxidase [at light 
microscopy or ultrastructural level] and/or CAE and the absence of ANBE 
(2,6,22,70). Leukaemias with cells containing both ANBE and CAE should be 
designated as myelomonocytic (8, 11). 
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4. Sudan Black 8 [SBB] - stains a variety of lipids, including neutral fats, 
phospholipids, and sterols, but may also stain some cellular elements that are 
not lipids. 
Lymphocytes and lymphoblasts may rarely stain with Sudan Black 8, while 
granulocytic precursors and immature monocytes show characteristic [strong 
localised and dense cytoplasmic] staining patterns. 
Myeloperoxidase, SBB and chloroacetate esterase have been reported to be much 
more sensitive for the detection of Auer rods than are the Romanowsky stains (92). 
Another advantage of these stains is that the agranular mature neutrophils in MOS or 
M2 cases can be recognized (23,34). 
Acid phosphatase shows a distinct localized pattern in the Golgi zone in T-ALL, and 
also in M6 and M7 blasts (2,6,38,70). 
Cytochemistry still remains the cheapest and quickest way of differentiating some types 
of the AL, but recently developed monoclonal antibodies for myeloid, monocytic, 
lymphoid, megakaryocytic and erythroid antigens have made the use of cytochemistry 
less essential. 
• IMMUNOLOGICAL CLASSIFICATION 
Immunological techniques are used to identify cytoplasmic and surface membrane 
antigens of leukaemic cells. Surface markers have been analyzed by various methods 
-immunofluorescence microscopy, immunocytochemistry and flow cytometry. The first 
two techniques have the advantage of direct cell analysis, but disadvantages include 
slow, tedious analysis. Flow cytometry has the advantages of a faster analysis, 
objectivity, reproducibility, and the ability to estimate cell size and granularity (6). 
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The expression of monoclonal antibody-defined myeloid antigen coincides with the 
pathways of normal haematopoietic differentiation within the myeloid lineage. [see 
Table 5] Immunological markers are important in the diagnosis of ANLL for many 
reasons. They allow some ANLL, which give negative reactions with SBB, MPO, and 
non-specific esterase, to be identified as myeloid and inappropriate antigen expression 
to be identified as bilineage and biphenotypic leukaemia. 
lmmunophenotyping is particularly important in the diagnosis of MO, M6 and M7, and 
when it is used to supplement the other subtypes there is an improvement in 
.. 
diagnostic accuracy. 
Approximately 3% of ANLL are negative in cytochemical tests, but show positivity with 
at least one myeloid monoclonal antibody CD13 or CD33 and the enzyme MPO 
demonstrated by immunocytochemstry and/or electron microscopy; these have been 
designated as MO (7). Monoclonal antibodies CDw41 and CDw42 have been used 
in flow cytometry and immunoalkaline phosphatase techniques to establish a diagnosis 
in acute megakaryocytic leukaemia (2,6, 10,70). 
Numerous monoclonal antibodies [McAb] are now available which help to identify 
specific types of ANLL (2, 7, 10, 11, 20, 22, 35, 64, 65, 76, 78, 79, 80, 81, 82, 87, 88, 
89, 90, 93, 97, 98, 99). 
• In general, these reagents do not react with lymphoblasts and have variable 
expression in the various type of ANLL. Some, such as CD 13, CD 33 and anti-MPO, 
are broad panmyelomonocytic markers that can be used to screen ANLL cases as 
they mark early myeloid precursors (83,91). Anti-MPO monoclonal antibodies were 
reported to be positive in up to 94% of ANLL, with 86% and 84% of CD 13 and CD 33 
positivity respectively (88). Also, monoclonal antibodies to glycophorin, the transferrin 
receptor [OKT-9] and CD 45, have been useful in difficult cases of M6 [see Table 5]. 
36 
Table 5: Cell markers in ANLL (2) 
r--------------------------------------------------------------------------, 
•M~b MO M1 M~M3 M~M5 MG M7 1 
~--------------------------------------------------------------------------1 
: CD34 + + +/- +/- - +/- : 
~--------------------------------------------------------------------------1 
: CD13 + + + + + + : 
~--------------------------------------------------------------------------1 
: CD33 +/- + + + +/- + : 
~--------------------------------------------------------------------------1 
: CD11 b - - + +/- - - : 
~--------------------------------------------------------------------------1 
: CD14 + : 
~--------------------------------------------------------------------------1 
: Glycophorin - - - - + - : 
~--------------------------------------------------------------------------1 
: CDw41/41 + : 
~--------------------------------------------------------------------------1 
: TdT -/+ -/+ l L--------------------------------------------------------------------------~ 
CYTOGENETIC ABNORMALITIES 
Mitotic disturbances in tumour cells were recognized by pathologists as early as the 
late 19th century. Identification in 1960 by Nowell and Hungerford of the Philadelphia 
chromosome in leukaemic cells from patients with chronic myelogenous leukaemia was 
a major breakthrough in the detection of chromosomal abnormalities. 
A new period began in the 1970's when banding techniques were developed that 
allowed better detection and definition of specific structural abnormalities not previously 
recognized. Finally, the current era, which began in the 1980's, has been 
characterized by considerable improvements in the quality of chromosome 
preparations available for meticulous analysis. More recently, techniques using cell 
synchronization and high resolution banding methods have facilitated the precise 
identification of non random chromosomal abnormalities in a variety of malignancies. 
As a result of these improvements such derangements have been reported in at least 
50% of patients with ANLL, although recent studies suggest that they may be as high 
as 80% (2). 
Both chromosome gains and losses may be seen in ANLL. With the exception of 
chromosome 16, which has never been observed as a gain, and chromosome 1, 
• 
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which was never lost, all the other chromosomes have contributed to numerical 
changes. The gain of chromosome 8, the most frequent abnormality seen in ANLL, 
results in trisomy 8 and has been observed in several FAB subgroups. The t[8;21] 
translocation occurs predominantly in the FAB M2 subtype but has been observed in 
the M4 and M 1 subtypes. 
The t[15;17] translocation found in the FAB M3 is most specific in that it occurs only 
in acute promyelocytic leukaemia. Recently, the molecular features underlying the 
t[15;17] translocation have been clarified. 
The breakpoint on chromosome 17 has been localized within the retinoid acid receptor 
alpha [RAR alpha] locus while that on chromosome 15 has been localized within a 
gene named promyelocytic [PML]. It is believed that the PML-RAR-alpha fusion 
product may generate an RAR alpha mutant that contributes to acute promyelocytic 
leukaemogenesis through interference with promyelocytic differentiation (6). 
The inv[16] and t[16;16] abnormalities have shown a strong correlation with acute 
myelomonocytic leukaemia with abnormal eosinophils [M4E] (77). Structural 
abnormalities of the long arm of chromosome 11 have been associated with acute 
monocytic leukaemia; in particular with the poorly differentiated form [M5a] found in 
children (6). 
• Some simple changes t[8;21] and inv[16] are reported to carry a relatively good 
prognosis, while others, affecting chromosomes 5 or 7, carry a poor prognosis [6]. 
A -5 and -7 chromosome abnormality is present in approximately 90% of patients with 
therapy-related ANLL, and is known to respond poorly to induction therapy (2,6,70). 
The relationship between chromosomal abnormalities and clinical or blast cell features 
is three-fold, and includes those strongly associated with a particular FAB type, those 
associated with morphological features of the marrow which do not contribute to the 
FAB classification, and those which are found throughout ANLL (2). 
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Table 6: Chromosomal abnormalities associated with FAB subtype or specific 
marrow morphology 
r--------------------------------~---------------~--------------------------, 
• Chromosome abnormalities FAB type Morphology • 
~--------------------------------~---------------~--------------------------1 
l t[8;21] M2 Myeloblasts l 
~--------------------------------~---------------~--------------------------1 
l t[15;17] M3 Promyelocytes l 
~--------------------------------~---------------~--------------------------1 
: M3 variant Promyelocytes with : 
: microgranules : 
~--------------------------------~---------------~--------------------------1 
: inv[16] M4E Abnormal eosinophils : 
: del[16] : 
~--------------------------------~---------------~--------------------------1 
: del or t[11] [ q23] M5 Mono blasts : 
: t[11][q13] Monocytoid : 
~--------------------------------~---------------~--------------------------1 
: t[6;9] Not specific Increased basophils : 
~--------------------------------~---------------~--------------------------1 
: inv[3] Thrombocytosis : 
~--------------------------------~---------------~--------------------------1 
l t[3;3] Abnormal : 
I I 
: megakaryocytosis : L--------------------------------~---------------~--------------------------~ 
(2,4,5,6,70) 
Abnormalities found throughout ANLL 
5 or 
-7 or 
5 and 
+8 
t/del 12p 
+21 
5q-
7q-
7 abnormalities 
ELECTRON MICROSCOPY 
Electron microscopy [EM] can be invaluable in the classification of particular subtypes 
of ANLL, particularly MO and M7. Peroxidase activity is present in the primary granules 
in blasts of the granulocytic series and shows reactivity in the nuclear membrane, 
endoplasmic reticulum, and Golgi region, and this can be used as a supportive 
investigation in cases of MO (6). Peroxidase has also been shown in megakaryoblasts, 
except that neither granules nor the Golgi apparatus show peroxidase activity, and 
positivity is confined to the nuclear space and endoplasmic reticulum (6,79,88). Some 
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combined studies employing both platelets peroxidase and immunological staining for 
megakaryoblast surface glycoproteins has revealed that the platelet peroxidase 
positivity appears earlier than does the detection of CDw41 and CDw42 antigens (6). 
Figure 9: 
PROGNOSIS 
Electron microscopy with myeloperoxidase cytochemistry showing 
presence of myeloperoxidase in primary granules of myelocyte. (x25 000] 
In the most recent MAC ANLL trial [1984-1988], the complete remission [CR] rate 
achieved with chemotherapy for those aged 60 or over was 41 %, for those between 
40 and 59 years 68%, and for those aged less than 40 years it was 83% (2). 
Median survival time is now 12 months for ANLL patients, and for those who enter 
remission 25% are alive 24 months and 10% 60 months after remission induction (4). 
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In a current study at Groote Schuur Hospital [GSH], 58% of 106 ANLL patients 
achieved complete remission after their first induction therapy, with a median duration 
of remission being 38 months and with 39% of relapses occurring during the first 24 
months. 
Allogenic bone marrow transplantation [BMT] from a fully HL.A-matched unreactive 
sibling offers an approximately 50% chance of long term disease-free survival [DFS] 
in children and young adults. In adults over the age of 40, long term DFS is not as 
good as it is in younger patients (2). Median post-bone marrow transplant survival at 
GSH is 65 months. 
Features which have been associated with a poor prognosis in ANLL include: age over 
60 years, a high peripheral white cell count, thrombocytopenia [less than 25 x1 o9 /L] 
at presentation, chromosome abnormalities particularly involving chromosomes 5 and 
7, (2,6) trilineage myelodysplasia, (60) and the presence of CD 34 positive blasts (82). 
TREATMENT 
A prerequisite for ANLL patients is induction of a profound bone marrow hypoplasia 
if they are to achieve complete remission (2). A combination of drugs is used which 
acts at different stages of the cell cycle, resulting in profound suppression of leukaemic 
cells and allowing recovery of normal haemopoietic cells (2,6) . 
Therapy in ANLL involves three stages - remission induction, consolidation and 
consideration of bone marrow transplant, and further intensification. 
For remission induction three drugs are used; daunorubicin, cytosine arabinoside and 
thioguanine or etoposide. Daunorubicin and cytosine arabinoside are the two most 
important drugs for ANLL therapy. As the main problem facing ANLL patients in CR 
is the possibility of leukaemic relapse, remission induction is followed by consolidation 
• 
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with further intensification by the use of, for example, mitozantrone in combination with 
cytosine arabinoside (2,100}. 
Recently, haematopoietic growth factors like granulocyte-macrophage colony 
stimulating factor [GM-CSF] have been given to patients before cytosine arabinoside, 
in order to stimulate proliferation of the leukaemic cells and to increase their sensitivity 
to chemotherapy, but there is as yet no evidence of an increase in remission rate or 
duration {100). 
An alternative approach is to try to induce maturation of leukaemic cells. The most 
important clinical studies of differentiating agents involved persons with APL receiving 
all-trans retinoic acid with more than 90% achieving remission, and this was followed 
by post-remission chemotherapy (101,102,103). 
In the Department of Haematology at GSH, treatment is divided into three phases, 
namely - remission induction with Fourth Cape Town Regimen [CTR IV], followed by 
consolidation with two courses of CTR IV and if possible by allogenic or autologous 
BMT. 
Fourth Cape Town Regimen comprises the following agents: cytosine arabinoside, 
epipodophyllotoxin, VP16-213 and daunorubicin. 
[The Cape Town Regimen for the Management of Acute Leukaemia. December. 1990] 
• 
• 
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CHAPTER THREE 
MATERIALS AND METHODS 
PATIENT SELECTION 
Thirteen cases of MOS and 16 cases of ANLL which had been diagnosed between 
May 1990 and July 1991 were evaluated. A decision was made to exclude patients 
with ALL, as cytochemistry does not play a major role in the diagnosis of this 
condition, and initial attempts with lymphoid monoclonal antibodies were unsuccessful. 
At the time of bone marrow biopsy, patients had not received specific therapy and the 
initial diagnosis and classification was made on the basis of blood and bone marrow 
smears. 
LABORATORY PROCEDURES 
Blood smears from each patient were stained with Wright-Giemsa stain: 
1. Wright-Giemsa stain 
Wright's stain powder [Sigma, Lot 520728] 9.0 g 
Giemsa stain powder [Merck, No 6241 O] 1.0 g 
glycerin [Merck, No 9907229] 90 ml 
methanol [absolute] [BDH, No R1680] 2910ml 
Reagents were mixed and stored in a brown bottle for 30 days prior to use. 
2. Phosphate buffer [pH 6.4] 
anhydrous monobasic potassium phosphate [BDH, Lot 2266030L] 
anhydrous dibasic sodium phosphate [BDH, No 30343] 
distilled water 
6.63g 
2.56 g 
1000 ml 
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3. Methyl alcohol [BDH, No 64186 H] 
Air-dried blood smears were fixed with methanol for 30 seconds, flooded with Wright's 
stain for four minutes, and placed in a mixture of equal volumes of phosphate buffer 
and Wright's stain for seven minutes. They were rinsed with tap water and air dried 
(94). 
Marrow aspirates - these were obtained by aspiration from the posterior superior iliac 
crest and stained with May-Grunwald-Giemsa. 
May-Grunwald-Giemsa staining procedure: 
May-Grunwald stain [Merck, Lot 832452]: 
A 0,3% solution of May-Grunwald powder in methanol was prepared by grinding, 
filtered after 2-3 days, and diluted before use with a phosphate buffer solution of pH 
7.2. 
Giemsa stain [Merck, No 6241 O]: 
0,6 gm Giemsa powder was added to 50 ml of methanol, and then 25 ml of glycerine 
was added. After 2-3 days, the solution was filtered and diluted before use with a 
phosphate buffer of pH 7.2 in 1 :1 O ratio. 
Air-dried smears of blood or bone marrow were fixed for 15 minutes in methanol, 
transferred to diluted May-Grunwald solution for 15 minutes, and then transferred to 
diluted Giemsa solution for 30 minutes. The smears were washed in a phosphate 
buffer [pH 7.2], and air-dried (104). 
In all patients, bone marrow biopsies were taken from the posterior superior iliac crest 
with a Jamshidi needle (gauge 8] and divided in half longitudinally in a specially 
designed holder. One half was used for paraffin processing, the other half for glycol 
methacrylate [GMA] embedding. Cores for GMA embedding were immediately placed 
• 
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in 50% acetone at -20 °c for two hours for fixation and dehydration and then at -20 °c 
for two hours in Solution A [Sol.A] (24), which consisted of: 
- hydroxyethyl-methacrylate [Merck-Schuchardt, No 830K10514743] - 100 ml 
- 2-butoxyethanol [Merck, No 9261276] 15 ml 
- benzoyl peroxide [Merck-Schuchardt, No 8259168] 1.0 g 
- methyl benzoate. [Merck, No 4563723] 6 ml 
The reagents were mixed in a bottle which was placed on a rotary-mixer for 2-4 hours 
at 4 °c. 
Embedding was done at -20 °c, in a mixture of 42 parts of Sol.A to one part of 
Solution B [Sol.BJ (24), which consisted of: 
- polyethylene glycol 400 [BDH, No 4763820G] 10 ml 
- NN dimethylaniline [BDH, No 9497320K] 1 ml 
Marrow cores were then submerged in the embedding mixture of Sol.A and Sol.B 
in embedding moulds, placed at the top of the bath filled with a mixture of water and 
ethylene glycol cooled to a temperature of -20 °c. [Fig.1 O] 
Figure 1 O: Water bath with embedding moulds placed at the top 
,,. 
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2.5 ml of the embedding mixture was required to embed an 8-1 O mm long marrow 
core. 
The polymerization reaction is initially strongly exothermic and if it is allowed to 
proceed rapidly without adequate cooling, the boiling point of the monomer is 
exceeded. This results in the formation of gas bubbles which are trapped in the block. 
This may impair the morphological assessment and also the cytochemical and 
immunological reactions. By placing the specimens in a vacuum, which is essential 
for proper tissue infiltration, the boiling point of the embedding solution is further 
decreased. Polymerization was therefore performed at -20 °c under a vacuum of 0.5 
atmospheres for 4 hours and this proved to be effective for uniform and adequate 
polymerization [Fig.11] and for the preservation of cytochemical and immunological 
activity. 
Figure 11: A marrow core, embedded in GMA attached to aluminium block holder 
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In a higher vacuum of more than 0,5 atmospheres, the polymerization reaction 
exceeded the boiling point of the embedding mixture with the formation of gas bubbles 
as previously described. 
Sections were cut with disposable hardened steel knives on a 2040 Reichert-Jung 
microtome into 2 microns sections, floated in a water bath at 25 °c, placed on slides 
and allowed to dry at room temperature. Sections not utilized immediately were stored 
in the freezer at -20 °c for varying periods, ranging from a few weeks to a few months. 
They were processed in batches for cytochemistry or immunophenotyping. 
All marrow sections were then routinely stained with: 
1. Haematoxylin and eosin: 
Haematoxylin (Harris haematoxylin] [Merck, Lot 09619162] was applied to sections for 
4 minutes and washed off with water. Sections were differentiated for 2-3 seconds with 
1 % acid-alcohol, washed and left to blue in running tap water for 10 minutes. 
Counterstain was then applied with 1 % aqueous eosin [Gurr, No 21028] for 2 minutes 
at room temperature, and sections were then washed, air dried and mounted in DePeX 
mounting medium [Gurr, No 36125] (104). 
2. Enzymatic reactions: 
Myeloperoxldase 
Sections were presoaked in normal saline for 15 minutes then preincubated for 1 O 
minutes at room temperature in 5 mg DAB [3,3 diaminobenzidine tetra hydrochloride] 
[BDH, 4948480H ] and dissolved in 1 O ml 0.05 M Tris buffer pH 7.6. 
0.1 ml of 1% H20 2 [Lennon] was added to DAB-Tris solution and incubated for 20 
minutes at room temperature. 
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Slides were rinsed three times with 0,05 M Tris buffer, counterstained with Harris 
haematoxylin for 5 minutes at 25 °c, air dried, and mounted in DePeX mounting 
medium (22). 
Chloroacetate esterase 
Preparation of reagents: 
1. Sol.A: 
0.01 g alpha-naphtha! AS chloroacetate [Sigma, Lot 105F - 5052] was dissolved 
in 0.5 ml N,N dimethylformamide. [Sigma, Lot 16C - 0050] 
2. Sol.B: 
0.1 ml New Fuchsin [Gurr, Lot 6840060N] was mixed with 0.1 ml 4% sodium 
nitrite [BDH, No 9909805] and left to react for 1 minute. 
9.5 ml of a phosphate buffer of pH 7.6 was added. 
Sol.A and Sol.B were mixed together and applied to sections for 1 hour at room 
temperature. 
After incubation, sections were rinsed with water, counterstained with Harris 
haematoxylin for 5 minutes, air-dried, and mounted with DePeX mounting 
medium (22). 
Alpha-naphthyl butyrate esterase 
1 O mg of alpha-naphthyl butyrate [Sigma, Lot 32H5002] was dissolved in 0.5 ml of 
ethylene glycol monomethyl ether [Merck, No 2048932] and 9.5 ml of 0.15 M 
phosphate buffer, pH 6.3 was added with 0,05 ml of pararosanilin 
[Sigma, Lot 118F-3709] working solution, which was made by mixing 1 gm of 
pararosanilin with 25 ml of 2 N HCI. 
Sections were incubated in the above solution at 25 °c for 1.5 hour, rinsed with water, 
counterstained in Harris haematoxylin for 5 minutes at 25 °c, air dried and mounted 
with DePeX mounting medium (22). 
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Alkaline phosphatase 
A stock solution was prepared by dissolving 30 mg naphthol AS phosphate 
[Sigma, Lot 77F - 5015] in 0.5 ml N,N-dimethylformamide [Sigma, Lot 16C - 0050] to 
which was added 100 ml of 0.2 M Tris buffer, pH 9.1. 
1 O mg of fast blue BB salt [Sigma, Lot 49F - 0040] was dissolved in 1 O ml of stock 
solution. Sections were incubated for 1.5 hour at 25 °c, rinsed with water, 
counterstained with 0.1 % aqueous neutral red [Gurr, No 23523] for 10 minutes at 
25 °c, air dried and mounted with DePeX mounting medium (22). 
Acid phosphatase 
Preparation of reagents: 
1. Michaelis veronal-acetate buffer stock solution: 
sodium acetate-3H20 
sodium barbiturate 
distilled water 
2. Incubation medium: 
[BDH, No 7438635] 
[BDH, No 4811880H] 
500.00ml 
9.714 g 
14.714 g 
naphthol AS phosphate [ Sigma, Lot 1 OOH - 5007] 10 mg 
dissolved in N,N-dimethylformamide 1 ml 
Michaelis stock solution 5 ml 
distilled water 12 ml 
1 gm of pararosanilin dissolved in 25 ml 2 N HCL 0.05 ml 
pH was adjusted to 6,3. 
The incubation medium was applied at 37 °c for 60 minutes and, after incubation, 
sections were rinsed with distilled water. Sections were then counterstained with Harris 
haematoxylin for five minutes at 25 °c and mounted with DePeX mounting medium 
(22). 
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Periodic acid Schiff 
1. Periodic acid solution: 
periodic acid crystals [BDH, No 58239308] 5 gm 
distilled water 500 ml 
2. Schiff's basic fuchsin: 
basic fuchsin [Gurr, Lot 6840060] 
hot distilled water 
5gm 
500 ml 
Filtered and saturated with S02 by bubbling for one hour. 
Filtration was repeated through Whatman No.1 filter paper into a dark bottle. 
Sections were incubated in 1 % periodic acid for 1 O minutes at 25 °c, rinsed with 
distilled water and incubated in Schiff's reagent for 30 minutes at 25 °c. After 
incubation, sections were washed in running tap water for 10 minutes, counterstained 
with Harris haematoxylin at 25 °c, air-dried, and mounted with DePeX mounting 
medium (105). 
In all enzymatic reactions positive and negative controls [peripheral blood smears] 
were stained simultaneously with GMA marrow sections. 
Gomori's Stain 
Methenamine silver solution: 
3% methenamine [Sigma, Lot 68F0059] 
distilled water 
sodium tetraborate [BDH, No 0245370] 
5% AgN03 [BDH, No 221535] 
25.0 ml 
25.0 ml 
2.0ml 
1.25 ml 
Sections were oxidized in 5% chromic acid [Merck, No CC580129] for one hour at 
room temperature, washed in tap water, then rinsed in sodium bisulphate [BDH, No 
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143104028] for one minute and again washed well in distilled water, and placed in 
methenamine silver solution at 56 °c for one hour. 
At this stage slides were washed with · warm water, toned in 0, 1 % gold chloride 
[SAARCHEM, No 19139] for 2-5 minutes, washed, fixed in sodium thiosulphate 
[SAARCHEM, No 18157] for 5 minutes and washed again in running tap water for 5 
minutes. 
Sections were counterstained in Light Green [Gurr, No 36829] solution for 30-40 
seconds, washed in water and mounted in DePeX mounting medium (105). 
3. Prussian blue: 
2% Potassium Ferrocyanide (Merck, No 24709] was mixed with 0.2 M HCI in equal 
volumes prior to staining and sections were immersed in this solution at 56 °c for 15 
minutes, then washed in running tap water for 20 minutes, counterstained with 
safranine (BDH, Lot 426937M] for 30 seconds, air-dried and mounted with DePeX 
mounting medium. 
In this procedure positive controls [red cells with Pappenheimer's bodies] were stained 
simultaneously with GMA marrow sections (105). 
4. lmmunophenotyping with anti-myeloperoxidase [anti-MPO] [DAKO, Lot 037], CD13 
[DAKO, Lot 01 O] and CD33 [DAKO, Lot 01 O] monoclonal antibodies: 
lmmunohistologic staining of GMA sections was performed by the double-conjugate 
indirect peroxidase method modified for plastic sections (99). 
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See diagram below with accompanying methodology explanation. 
3,3'-Diaminobenzidine 
Horseradish peroxidase-
conjugated swine anti-
rabbit immunoglobulin 
Horseradish peroxidase 
-conjugated rabbit 
anti-mouse immunoglobulin 
Primary mouse 
monoclonal antibody 
Antigen 
Sections were allowed to hydrate for 15 minutes in O.OSM Tris-buffeted saline, [TBS] 
pH 7.6 
Nonspecific binding of peroxidase was blocked by incubation with 2% normal swine 
serum in TBS for 30 minutes at 37 °c. 
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Sections were then incubated with appropriate dilutions [1:100] of mouse monoclonal 
antibodies [DAKO] in TBS at 37 °c for 2 hours with anti-MPO antibody, and overnight 
at 4 °c with CD13 and CD33 monoclonal antibodies. 
After two 5 minute washes in TBS, the sections were incubated in a 1 /40 dilution of 
horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin [DAKO, Lot 089] 
in TBS with 2.5% human AB serum for 1 hour at 37 °c. 
After TBS washing, the sections were incubated in a 1 /40 dilution of horseradi~h 
peroxidase-conjugated swine anti-rabbit immunoglobulin [DAKO, Lot 030] in TBS with 
2,5% human AB serum for 1 hour and subsequently washed in TBS at 37 °c. The 
peroxidase reaction was developed with 3,3'-diaminobenzidine 0.05% [DAB] [Sigma] 
in 0.05 M TBS, pH 7.6, with 0.1 % H20 2 for 10 minutes at room temperature, washed 
in distilled water, counterstained with Harris haematoxylin for 5 minutes at 25 °c, blued 
in running tap water, air-dried, and mounted with DePeX mounting medium. 
As a positive control GMA embedded marrow sections of a known case of ANLL were 
used, and these showed characteristic paranuclear positivity for myeloperoxidase. 
Negative controls [no primary antibody applied] were processed simultaneously 
with GMA marrow sections . 
MORPHOLOGIC CRITERIA 
In each case (for both cytology and biopsies), 500 cells were counted to establish a 
differential count of blasts, myeloid and erythroid precursors, lymphocytes, plasma 
cells and the myeloid/erythroid ratio. 
In addition, the percentage of ring sideroblasts was established by counting 100 
nucleated cells on Prussian blue stained samples. 
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In each case the following features were evaluated: 
number of blasts, cellularity, signs of dyserythropoiesis [multinuclearity, nuclear 
fragments, cytoplasmic abnormalities, number of erythroblasts [ <5%, >60%] and of 
ring sideroblasts [>15%], dysmegakaryopoiesis, [micromegakaryocytes, large 
mononuclear forms, multiple small nuclei], dysgranulopoiesis, [nuclear abnormalities -
pseudo Pelgar-Huet forms, hypogranular cells] and the number of monocytes in the 
peripheral blood. 
Architectural distortion of the marrow was also assessed in MOS and cytochemical 
staining was applied in all patients and immunophenotypic in selected cases. 
The following criteria were used for the grading of collagen reticulin in marrow 
sections: (106) 
r-----------------~-----------------------------------------------------------------, 
: Grade N or 1 + No or occasional fine collagen fibres only. l 
~-----------------~-----------------------------------------------------------------~ 
: Grade 2+ Fine collagen fibres forming a network throughout most : 
: of the sectors. : 
~-----------------~-----------------------------------------------------------------~ 
: Grade 3+ Diffuse fibre network with scattered thick coarse fibres. l 
~-----------------~-----------------------------------------------------------------~ 
: Grade 4+ Diffuse, often coarse fibres with collagenization. l L-----------------~-----------------------------------------------------------------~ 
The cellularity of aspirate and biopsy samples was assessed as below: 
r-----------------~------------------------, 
: 10-25% grossly hypocellular. : 
~-----------------~-----------------------~ 
: 25-40% mildly hypocellular. : 
~-----------------~------------------------~ 
: 40-60% normocellular. : 
~-----------------~------------------------~ 
: 60-90% mildly hypercellular. l 
~-----------------~------------------------~ 
: >90% grossly hypercellular. : 
L-----------------~------------------------~ 
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Criteria used for grading iron stains in bone marrow aspirates: (107) 
r-----------------~-----------------------------------------------------------------, 
, Grade O No iron granules observed. 1 
~-----------------~-----------------------------------------------------------------1 
: Grade 1 + Small granules in reticulum cells, seen only with oil- : 
: immersion lens. [x400] : 
~-----------------~-----------------------------------------------------------------1 
, Grade 2+ Few small granules visible with low-power lens. [x100] , 
~-----------------~-----------------------------------------------------------------1 
, Grade 3+ Numerous small granules in all marrow particles. • 
~-----------------~-----------------------------------------------------------------1 
• Grade 4+ Large granules in small clumps. , 
~-----------------~-----------------------------------------------------------------1 
• Grade 5+ Dense, large clumps of granules. • 
~-----------------~-----------------------------------------------------------------1 
, Grade 6+ Very large deposits, obscuring marrow detail. , 
L-----------------~-----------------------------------------------------------------~ 
Criteria used for grading iron stores in bone marrow GMA embedded sections: 
r-----------------~-----------------------------------------------------------------, 
: Grade O No iron granules observed. : 
~-----------------~-----------------------------------------------------------------1 
: Grade 1 + Single, occasional iron granules seen in reticulum cells. : 
~-----------------~-----------------------------------------------------------------1 
: Grade 2+ Iron granules easily visible in reticulum cells with low- : 
: power lens. [x100] : 
~-----------------~-----------------------------------------------------------------1 
l Grade 3+ Numerous small iron granules seen in reticulum cells. I 
~-----------------~-----------------------------------------------------------------1 
l Grade 4+ Large iron granules seen in reticulum cells. l 
~-----------------~-----------------------------------------------------------------1 
l Grade 5+ Reticulum cells are heavily laden with iron granules. l 
~-----------------~-----------------------------------------------------------------1 
l Grade 6+ Reticulum cells are numerous and heavily laden with l 
! large iron granules, obscuring marrow detail. ! L-----------------~-----------------------------------------------------------------~ 
• 

• 
57 
CHAPTER FOUR 
RESULTS 
PATIENT DATA 
Thirteen cases of MOS and 16 of ANLL diagnosed between May 1990 and July 1991 
were evaluated prior to treatment. 
MOS patients consisted of RA [2], RARS [2], RAES [2], RAEB-t [3] and CMML [4]. 
ANLLincluded M0[1], M1 [6], M2[3], M3[2] M4[1], M4E[1], M6[1]. Onetrephine biopsy 
from this group could not be assessed as it was extensively necrotic. 
LABORATORY DATA 
MDS PATIENTS 
Of the 13 cases one was female and twelve were male, with a median age of 68 years, 
the age range being 35-7 4 years. 
12 patients were anaemic [haemoglobin less than 120 g/L] with a range of 56-130, 7 
were leukopenic [white cell count less than 4 x109 /L] with a range of 1,2-38 and 6 
were thrombocytopenic [platelet count less than 140 x109 /L] with the range being 
between 13 and 680. 
An increased monocytic component in the peripheral blood [more than 1 x109 /L] was 
noted in 4 subjects [No's 3, 4, 9, 12]. 
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Two patients had markedly increased blast counts in the peripheral blood, and Auer 
rods were noticed in only one case [see Table 7]. 
Table 7: Age, sex, and presenting haematological peripheral blood indices 
Patient Sex Age Hb wee Mon Pit Blasts Auer 
No years g/L x109 /L % x109 /L % rods 
1. M 72 103 4,0 15 13 3 -
2. M 67 83 4,7 1 191 - -
3. M 70 101 8,8 30 195 - -
4. M 67 107 3,8 28 165 - -
5. M 68 130 1,5 6 226 - -
6. M 54 87 2,6 7 17 1 -
7. M 53 89 1,5 2 39 3 -
8. M 65 97 3,0 9 27 - -
9. F 74 56 4,8 22 285 - -
10. M 68 82 1,2 4 75 46 -
11. M 35 60 2,4 6 680 - -
12. M 73 74 38,0 13 178 - -
13. M 39 102 8,9 2 43 35 + 
Abbreviations: Hb - haemoglobin, wee - white cell count, Mon - monocyte count, 
Pit - platelet count, + present, - not present. 
ARCHITECTURAL DISTORTION 
Normally, marrow erythroid precursors are present intertrabecularly in small clusters, 
in different stages of maturation. Early myeloid precursors are in proximity to the 
endosteal surfaces of trabeculae and to arterial vessels, whereas mature forms are 
scattered throughout the central intertrabecular areas. A distortion of this topographic 
distribution is found in several diseases, but typically in MOS. Distortion of normal 
marrow architecture was observed in 8 cases : [No's 1, 2, 6, 7, 8, 11, 12, 13]; whereas 
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abnormal localization of immature precursors [ALIP] was noticed on biopsy in four 
cases. [No's 6, 10, 11, 13] [Fig.6] 
CELLULARITY 
In 11 cases marrow sections were hypercellular, in one case it was normocellular, and 
hypocellular in one [Fig.12]. 
Figure 12: Hypocellular marrow in MDS, showing chloroacetate esterase activity in 
myeloid precursors. [x100] GMA 
Cellularity was found to be similar on marrow sections and on marrow smears in 8 out 
of 13 cases. Aspiration failed in two cases. [No's 6, 1 O] [see Table 8]. 
60 
Table 8: Bone marrow cellularity on aspirate [BMA] versus biopsy sections [BMB]. 
10<25% 25<45% 45<60% 60<90% 90<100% Total[BMA] 
--------------~---------~--------------~---------~---------~--------- -~-------------DT 1 1 2 
-------------------------------------------------------------------------- - -------------10<25% 0 0 
-------------------------------------------------------------------------- - -------------25<45% 0 0 
--------------~---------~--------------~---------~---------~-----------~-------------45<60% 1 1 
-------------------------------------------------------------------------- - -------------60<90% 6 3 9 
---------------------------------------------------------------------------- -------------90<100% 
I Total[BMB] 1 
Abbreviations: 
8MB - bone marrow biopsy 
BMA - bone marrow aspirate 
DT - dry tap 
BLASTS 
0 
1 1 
1 7 4 13 
Agreement in blast counts was observed in only 7 out of 13 cases, with marrow 
sections showing higher counts, resulting in a change of diagnosis and prognosis in 
six patients. 
Two aspirates failed [No's 6, 1 O], and the blast count in one of these patients on 
paraffin sections was extended to be 10%, as against 60% on GMA sections. 
Biopsy blast counts in two subjects was higher than 30%, resulting in a diagnosis of 
ANLL. [No's 1 O, 13] In two cases of CMML [No's 4, 12] the diagnosis was changed 
on biopsy sections to RAES, and in two further patients [No's 6, 11] an alteration was 
made from RA and RARS respectively to RAES [see Table 9]. 
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Table 9: Blast infiltration on aspirate [BMA] versus marrow biopsies [8MB] 
<5% 5-20% 20-30% >30% Total[BMA] 
------------------------------------------------------------------------- -~ ------------DT 1 1 2 
-------------------------------------------------------------------------- ~ ------------
<5% 4 3 7 
-------------------------------------------------------------------------- ~-------------5-20% 2 1 3 
--------------~-------------~-------------~-------------~--------------~-------------20-30% 1 1 
---------------------------------------------------------------------------~-------------
>30% 
I Total [8MB] 4 
Abbreviations: 
8MB - marrow sections 
BMA - marrow aspirate 
OT - dry tap 
DYSHAEMOPOIESIS 
0 0 
6 1 2 13 
Marrow aspirate failed in two patients. Quantitative and qualitative changes in 
erythropoiesis were as easily assessed on aspirates as on marrow sections, although 
in four cases aspirates did not show dyserythropoiesis. Quantitative and qualitative 
features of dysmyelopoiesis and dysmegakaryopoiesis were more apparent on marrow 
biopsies [see Table 10] . 
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Table 10: Summary of the differences in dyshaemopoiesis between smears and 
marrow sections 
Red cell series Biopsy Aspirate 
-----------------------------~----------~----------Quantitatively disturbed 7 7 
Dyserythropoiesis 9 8 
Normal 0 4 
White cell series 
~----------------------------~----------~----------Quantitatively disturbed 7 4 
Dysmyelopoiesis 10 6 
Normal 0 5 
Megakaryocytic series 
-----------------------------------------------------Quantitatively disturbed 9 3 
Dysmegakariopoiesis 13 7 
Normal 0 5 
Table 11: Summary of morphological features found in aspirates and the GMA-
embedded sections 
Patient 
Cellularlty Blasts 
!No A H I A H I 
1. 80%; 80% 
2. 70% 90% 
3. 60% 80% 
4. 
5. 
6. 
7. 
8. 
9. 
70% 95% 
60% 80% 
DT 60% 
50% j 50% 
70% I 60% 
70% J 70% 
10. DT / 10% 
11. 70% j 90% 
12. 80% ( 75% 
13. 90% j 90% 
Abbreviations: 
25% 23% 
<5% j <5% 
4% j 4% 
<5% j 16% 
2% l 0% 
DT ' 8% 
10% 11% 
7% 6% 
4% ' 4% 
DT 60% 
2% • 20% 
0% • 16% 
18% ' 32% 
RS 
A H 
ND 
15% 
. 
. 
PS 
- ND 
ND -
>15% ) >15% 
DT >15% 
PS 
>15% 
DT 
>15% 
-
PS l 
<15% 
<15% 
>15% 
<15% 
DysE 
I A 
+ + 
. 
+ + 
. 
. 
+ + 
. 
+ + 
DT + 
+ + 
. 
+ 
. 
+ 
DT -
+ + 
. 
+ l + 
DysG 
+ + 
+ + 
+ + 
DT + 
+ + 
+ + 
DT + 
- + 
- + 
+ + 
DysM 
+ l + 
: I : 
+ + 
' 
~T 1 : 
- l + 
- i + 
+ + 
DT + 
+ + 
- + 
+ + 
Diagnosis 
A [AH] H 
RAEB-t 
RA 
CMML 
CMML CMMLJRAEB 
RARS 
RA RAEB 
RAEB 
RAEB 
CMMlJRARS 
(RAEB-t] ANLL 
RARS RAEB 
CMML CMMLJRAEB 
RAEB-t ANLL 
A - aspirate, H - histology, [AH] - aspirate and histology, + present, - not present, 
PS - pathological sideroblasts, RS - ring sideroblasts, DysE - dyserythropoiesis, 
DysG - dysgranulopoiesis, DysM - dysmegakaryopoiesis, OT - dry tap, [RAEB-t] -
diagnosis made on marrow paraffin sections. 
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CYTOCHEMICAL FINDINGS 
Chloroacetate esterase was found to be a very sensitive marker of myeloid cells and 
also mast cells, which appeared to be very prominent in several cases. This stain can 
also be used to demonstrate dysplasia in myeloid precursors as it shows uneven 
cytoplasmic staining [Fig.13]. 
Figure 13: Chloroacetate esterase from MOS case showing myeloid cells at different 
stages of maturation, with uneven cytoplasmic staining in some of the 
cells. [x400) GMA 
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Alpha-naphthyl butyrate esterase did not stain the monocytic component in GMA-
embedded sections, showing positivity only in the reticulum cells [Fig.14]. 
Figure 14: Alpha-naphthyl butyrate esterase showing positivity in an elongated, large 
reticulum cell. [x400] GMA 
PAS stain showed distinct block positivity in erythroid precursors in the RAEB-t case, 
which was transforming into acute leukaemia- M6 [case No.1] [Fig.15]. 
Figure 15: PAS cytochemistry from a case of RAEB - transforming into 
erythroleukaemia showing block positivity in the cytoplasm of abnormal 
erythroblasts. [x1000] GMA 
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Acid phosphatase positivity was very distinct in osteoclasts [Fig.16] and reticulum cells 
[Fig.17]. It can therefore be a good marker of their activity in the marrow. 
Figure 16: Acid phosphatase cytochemistry from a case of MDS showing distinct 
cytoplasmic positivity in osteoclasts. [x1000] GMA 
Figure 17: Acid phosphatase cytochemistry from MDS case showing strong positivity 
in reticulum cells. [x600] GMA 
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Gomori's stain was unsuccessful as a stain for reticulum in GMA-embedded marrow 
sections [no reticulum was shown even in cases with marked increases in reticulum 
in routine paraffin sections]. 
Alkaline phosphatase appeared to be a very sensitive stain for reticulum as well as for 
alkaline phosphatase positive reticulum cells [AL-RC], (22) which in some cases were 
very prominent [Fig.18]. 
Figure 18: Alkaline phosphatase cytochemistry from a case of MOS showing presence 
of alkaline phosphatase positive reticulum cells [AL-RC] [x1000) GMA 
Recently it has became evident that two cell types seem to be of particular importance: 
one is a non-phagocytic cell (AL-RC], which stains for alkaline phosphatase, is 
dendritic in shape [Fig.18], and closely associated with granulocytic precursors (108). 
The other is a macrophage commonly associated with erythroid precursors. 
Dilly and Jagger (108) reported markedly increased numbers of AL-RC cells in all 
studied cases of ANLL and severe reduction of AL-RC in ALL An increase in their 
numbers was observed in some cases of MOS when they were also associated with 
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an increase in reticulum (22). An increase in the number of AL-RC was observed in 
8 individuals [in some this was very prominent]. 
Several studies reported that chondrocytes, osteoblasts, and endothelial cells of small 
arterioles [Fig.19] are also reactive with alkaline phosphatase (22,108). 
Figure 19: Alkaline phosphatase cytochemistry from a case of ANLL showing 
positivity in endothelial cells of a small arteriole. [x600] GMA 
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Alkaline phosphatase was performed in all except two cases, and in cases No's 1, 2, 
5, 7, 10, 11, 12, 13 showed marked increases in reticulum [1 + or more] [Fig.20]. 
Figure 20: Alkaline phosphatase cytochemistry from an MDS case showing markedly 
increased reticulum [x400] GMA 
IRON STUDIES 
GMA sections showed good quality iron staining with Prussian blue [Fig.21], and this, 
• together with excellent morphology, allowed for easy and accurate detection of ring 
and pathological sideroblasts [Fig.22]. 
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It also made it possible to detect the presence of stainable iron at the surface of 
trabecula bone in RARS cases [Fig.23]. 
Figure 23: Prussian blue stain from a case of RARS showing the presence of 
stainable iron at the surface of trabecula bone. (x1000] GMA 
The amount of iron present in marrow aspirate particles is comparable to the iron that 
is in reticulum cells on marrow sections, with only slight differences, but full 
concordance was observed in only four subjects [see Table 12]. 
More than 15% of RS was observed on both the aspirate and biopsy in cases 5 and 
9, with the former showing the higher percentage. In case 11 only occasional RS were 
detected on marrow sections, while the aspirate showed 15% of these cells. In case 
8 occasional RS were detected only on the marrow sections. The sections showed 
the presence of 49% RS, while the aspirate failed in patient 6. Aspirate also failed in 
case No 10 (see Table 12]. 
Figure 21: 
Figure 22: 
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Prussian blue stain from a case of RARS showing reticulum cells heavily 
laden with iron. [x400] GMA 
Prussian blue stain from a case of RARS showing the presence of ringed 
sideroblasts. [x1000] GMA 
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Table 12: 
Patient No A H 
1 ND 2/6 
2 1/6 1/6 PS 
3 1/6 ND 
4 ND 1/6 
5 4/6 58%RS 5/6 41%RS 
6 OT 5/6 49%RS 
7 4/6 PS 2/6 <15%RS 
8 0/6 0/6 <15%RS 
9 5/6 50%RS 3/6 26%RS 
10 OT 3/6 
11 4/6 15%RS 3/6 OCRS 
12 1/6 1/6 
13 4/6 4/6 
Abbreviations: 
A - aspirate, H - histology, ND - not done, RS - ring sideroblasts, OCRS -occasional 
ring sideroblasts, PS - pathological sideroblasts, OT - dry tap. 
CYTOGENETIC ABNORMALITIES 
Six out of thirteen patients had karyotypic abnormalities. Two showed 5q- abnormality, 
which is characteristic for MOS and is common in all subtypes except CMML. The 
t [8;21] translocation observed in case 13 is unusual for MOS and is predominantly 
present in M2-ANLL (2,84} [see Table 13]. 
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Table 13: 
Patient No Cytogenetlc abnormality 
1 Sq-, 7q-, 9q-, 17p+, 
6 1p-, 2p+, t[Sq;12q]. t[2q;3p] 
8 -16, t[1 ;16] 
10 46, XY, Sq-
11 47, XY, +21 
13 t[8;21] 
FINAL DIAGNOSTIC CONCORDANCE 
Agreement in a final morphological diagnosis was observed in 7 out of 13 patients. 
In two out of the six discordant cases histopathological diagnosis was already ANLL-
M2, and in the remaining four cases, the morphological diagnosis was RAEB as 
opposed to RA, RARS, and two cases of CMML [see Table 14]. 
Table 14: Concordance between marrow aspirate [SMA] and marrow biopsy [SMB] 
RA RARS RAES RAES-t CMML ANLL Total[SMA] 
-------------------------------------------------------------------------. -------------RA 1 1 2 
---------------~-------~-------~-------~----------~--------~-------. -------------RARS 1 1 2 
--------------------------------------------------------------------------- -------------RAES 2 2 
------------------------------------------------------------------------- -~ ------------RAEB-t 1 2 3 
------------------------------------------------------------------------- -~ ------------CMML 2 2 4 
~-------------~-------~-------~-------~----------~--------~------- -~ -----------. ANLL O 0 
I Total [8MB] 1 1 6 1 2 2 13 
Abbreviations: 
8MB - marrow sections 
BMA - marrow aspirate 
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II 
ANLL PATIENTS 
There were 8 females and 8 males with a median age of 44 years, the range being 
between 17 and 85 years. All patients were anaemic at presentation [Hb less than 120 
g/L] with a range of 45-114. Ten had a wee higher than 10 x109 /L, 5 had wee less 
than 4 x109 /L and all 16 patients were thrombocytopenic with platelet counts of less 
than 140 x109 /L, the range being between 14 and 135. 
An increased monocytic component in the peripheral blood [more than 5 x109 /L] was 
noted in two patients. 
The percentage of blasts in the peripheral blood varied from 3% to 96%, and Auer 
rods were found in 9 subjects [see Table 15]. 
Table 15: Age, sex, and presenting haematological peripheral blood indices 
Patient Sex 
No 
1. M 
2. F 
3. F 
4. F 
5. F 
6. F 
7. M 
8. M 
9. M 
10. M 
11. F 
12. M 
13. F 
14. M 
15. F 
16. M 
Abbreviations: 
Age Hb g/L wee Mon Pit Blasts Auer 
years x109 /L % x109 /L % rods 
17 75 0,9 0 93 6 -
46 87 145,0 0 96 96 + 
30 63 1,7 1 135 66 -
57 68 32,5 54 41 5 + 
46 81 178,8 3 14 86 + 
85 76 31,5 0 36 45 -
17 59 18,5 2 81 83 -
56 102 2,5 14 80 48 + 
23 112 22,4 1 35 68 + 
44 92 77,9 0 35 90 + 
58 72 3,9 0 46 80 + 
50 101 5,3 5 48 68 + 
34 114 10,3 1 26 31 -
49 77 308,8 11 33 89 -
25 45 40,0 10 39 87 + 
40 62 2,6 10 41 3 -
Hb - haemoglobin, wee - white cell count, Mon - monocyte 
count, Pit - platelet count, + present, - not present. 
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CELLULARITY 
In almost all cases, bone marrow cellularity in biopsy sections was concordant with 
that on the aspirate, with the exception of two cases in which the aspirate showed 
slightly higher cellularity [see Table 16]. 
Table 16: Bone marrow cellularity on aspirate [BMA] and biopsy sections [BMB] 
10<25% 25<45% 45<60% 60<90% 90<100% Total[BMA] 
--------------------------------------------------------------------------- - -------------10<25% 0 0 
--------------------------------------------------------------------------- - -------------25<45% 0 0 
----------------------------------------------------------------------------- -------------45<60% 0 0 
----------------------------------------------------------------------------- -------------60<90% 1 3 4 
--------------~----------~------------~----------~----------~--------- . ------------. 90<100% 1 10 11 
I Total[BMB] 0 
Abbreviations: 
· 8MB - bone marrow biopsy 
BMA - bone marrow aspirate 
BLASTS 
1 0 4 10 15 
In 7 cases the marrow aspirate blast count was higher than that estimated on the 
marrow sections, while eight cases showed similar counts on both aspirate and 
marrow sections [ see Table 17]. 
Table 17: Blast infiltrate on aspirate [BMA] and biopsy sections [BMB] 
<20% 20<40% 40<60% 60<80% >80% Total[BMA] 
-'<'2oo1o-------~----o----~----------~----------~----------~--------- - ------o -----
------------------------------------------------------------------------ - -------------· 20<40% 0 0 
--------------~---------~----------~----------~----------~--------- -~------------40<60% 3 3 
------------------------------------------------------------------------ --- -----------
~<00% 1 1 0 2 
------------------------------------------------------------------------ --- ----------->80% 1 2 2 5 10 
I Total[BMB] O 2 6 2 5 15 
Abbreviations: 8MB - bone marrow biopsy 
BMA - bone marrow aspirate 
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DYSHAEMOPOIESIS 
Dysplastic features were not prominent in any patients, except cases No's 4, 12, and 
16 [see Table 18]. 
Table 18: Summary of morphological features present in marrow aspirate and 
biopsies 
j Patient I Cellular I Blasts I RS I DysE I DysG I DysM I 
j No I A H I A H I A H I A H IA HIA HI 
1. 90% 95% 90%P j 95%P • • + + - • • · 
2. 90% ' 90% >90% j 80% - ' • ' ' 
3. 90% ' 95% >90% i OO°A, • ' • , , • ' + 
4. 80% ' 90% 80% : 32% - - + - + + 
5. 90% ' 9()0,<, 85% ' 90% - ' - ' ' 
' 6. --·-- ----··:··---- -- :- -- :·-
7. 90% j 100% 86% j 76% - • • ' + · , · · . • 
8. 90% j 95% 95%P j 82%P • - • ' • - - • ' • 
9. 90% j 90% 70% j 47% - PS - + + - - -
10. 90% j 70% 90% j 55% • < 15% - ' - - - • ' -
11. 70% j 70% 86% j 70% - • • • • • • • • • • 
12. 60% j 40% 43% • 53% • <15% • ' + + ' + • ' · 
13. 80% 1 70% 51% ' 55% • • • • • + + ... 
14. 90% ; 1()0% 88% ' 33% - - - - - + - -
15. 90% 1100% 87% • 50% - • • • - - • + . . . 
16. 70% 1 80% 50% • 45% - • + ' + + . . . . + 
Abbreviations: 
Diagnosis 
A [AH] H 
M3 
M1 M2 
MO 
M4 
M1 
M1 
M3 
M2 
M1 M2 
M1 M2 
M2 
M2 
M4E 
M1 M2 
M6 
.1 
A - aspirate, H - histology, [AH] - aspirate and histology, Cellular - cellularity, 
DysE - dyserythropoiesis, DysG - dysgranulopoiesis, DysM - dysmegakaryopoiesis, 
PS - pathological sideroblasts, RS - ring sideroblasts, - not present, + present, 
P - promyelocytes. 
One biopsy [No 6] could not be assessed because of extensive marrow necrosis. 
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CYTOCHEMICAL FINDINGS 
A diagnosis of ANLL was possible in 7 patients, [No's 2, 4, 5, 7, 11, 14, 16] who all 
showed more than 3% myeloperoxidase positivity in their blasts in the biopsy sections 
[see Table 19]. Two cases of M3 showed strong [more than 95%] positivity for 
myeloperoxidase in promyelocytes [Fig.24]. 
Figure 24: Myeloperoxldase cytochemistry from a case of APL showing coarse positivity 
in hypergranular promyelocytes. [x400] GMA 
.. In case no. 8 the chloroacetate esterase showed the presence of numerous Auer rods 
[Fig.25]. 
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Figure 25: Chloroacetate esterase cytochemistry from a case of APL showing coarse 
positivity and Auer rods in some of the promyeloctes. [x400] GMA 
Myeloperoxidase cytochemistry in patient 3 was negative [less than 3%] on both the 
aspirate and marrow sections. 
In four out of six negative for myeloperoxidase on plastic sections patients [case no's 
9, 10, 12, 13], the chloroacetate esterase showed very strong positivity in blasts, thus 
supporting a diagnosis of ANLL. In the remaining two negative cases, the diagnosis 
of ANLL had to be aided by immunophenotyping [No's 3, 15]. In the single example 
of M4E [No 14] chloroacetate esterase stain showed the expected abnormal positivity 
in eosinophils [Fig.8]. 
In six out of fifteen individuals reticulum was markedly increased [more than 1 + in 
grading]. In all four discrepant cases [No's 2, 10, 11, 15] a significantly increased 
reticulum was found on biopsy [at least 2+ on a grading scale]. 
An increase in the number of AL-RC was observed in 12 ANLL individuals. 
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Prussian blue showed only marginal differences in the amount of iron present in 
marrow aspirate particles and marrow sections. Case No 6 could not be assessed as 
the marrow was markedly necrotic. 
Table 19: Summary of cytochemical findings 
I Patient I Peroxidase I CAE I PAS 
I No I A H I A H I A H 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
100%Pj 100%P ND 80%P ND ND 
~ I ~ ~~ N_D ~~ : : 
24% i 15% ND 30% ND ' ND 
87% j 20% - - ND , -
97% j 40% ND i 20% ND j -
98%P i 95%P ND : 80%P ND i -
99% l - ND 80% ND ' -
3% l - ND 80% ND ' -
83% : >3% ND - ND 
88% ' - ND 8{)0,{, ND ' -
90% ' - ND 80% ND ' -
. . 
60% 30% ND 30% ND 80% 
92% ' - ND ! E~+ ND ' -
ND / 95%NS ND l 10% ND ; -
Abbreviations: 
I ANBE I Ac.Phos I A1.Phos I Pruss.a I 
I A H I 
ND ::::::: - ND l 2+ ND l 0/6 
- ' - - ND ! 2+ ND ! 3/6 
- ' - - - ND i 1 + ND l 0/6 
- - - ND l 1 + 1/6 l 1/6 
ND j - - : ND ND j ND 3/6 ! 3/6 
ND j ND ND ! +R ND j N ND j 1/6 
- i - - i +R ND i 1 + 2/6 i 2/6 
ND l - ND : - ND i N 3/6 j 3/6 
- ' - ND ' - ND i 3+ ND i 4/6 
- - 65%NS i - ND i 2+ 2/6 i 3/6 
- - ND : - ND i 1 + ND i 1/6 
- - - - ND i 2+ 2/6 i 1/6 
. . . 
- - - - ND ! 1 + 1/6 ! 1/6 
- ' - - - ND ! 2+ 2/6 ! 2/6 
ND ' - ND - ND j 3+ 3/6 j 2/6 
A - aspirate, H - histology, CAE - chloroacetate esterase, PAS - periodic acid Schiff, 
Ac.Phos - acid phosphatase, ANBE - alpha-naphthyl butyrate esterase, 
AI.Phos - alkaline phosphatase, Pruss.8- Prussian blue, PS- pathological sideroblasts, 
RS - ring sideroblasts, 8 - blasts, - negative, + positive, P - promyelocytes, 
R - reticulum cells, Eo - eosinophils, NS - non specific, ND - not done. 
IMMUNOPHENOTYPING 
lmmunophenotyping with myeloid antibodies [anti-MPO, CD 13 and CD 33] was 
performed in four selected patients [No's 3, 11, 14, 15] by using the double-conjugate 
indirect peroxidase method (99). Anti-MPO antibody [Fig.26] was found to be a very 
sensitive and reliable marker and was strongly positive in all tested cases. 
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Figure 26: lmmunophenotyping with anti - myeloperoxidase antibody from a case of MO 
ANLL showing strong perinuclear myeloperoxidase positivity. [x1000) GMA 
Positivity with CD 13 and CD 33 was achieved in only two cases, after overnight 
incubation with primary antibody [No's 3, 15] [Fig.27, 28]. 
Figure 27: lmmunophenotyping with CD 13 antibody from a case of M1 ANLL showing 
perinuclear positivity. [x1000] GMA 
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Figure 28: lmmunophenotyping with CD 33 antibody from a case of M1 ANLL showing 
perinuclear positivity. [x1000] GMA 
CYTOGENETIC ABNORMALITIES 
Cytogenetic abnormalities were detected in eight out of sixteen evaluated patients, with 
typical t[15; 17] for M3 in two patients, inv[16] for M4E in one and t[8;21] for M2 in 
three cases. Case No. 15 with the t[8;21] abnormality was classified on aspirate as 
M1, and on biopsy as M2, which is the more likely association {84) [see Table 20]. 
Table 20 
Patient No 
1, 8 
9, 13, 15 
14 
11 
16 
Cytogenetic abnormality 
t[15;17] 
t[8;21] 
inv 16 
-17, -22, t[13;15] 
45, XY,-7 
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FINAL DIAGNOSTIC CONCORDANCE 
Table 21 shows the distribution of the 15 studied cases according to the FAB 
classification. The largest group of patients [10) were M1 and M2 categories. In 11 
cases overall concordance has been shown between marrow sections and aspirate 
on cytomorphological, cytochemical, and immunogenic criterias. 
Differences were noted in the degree of maturation of granulocyte precursors, which 
was more pronounced in the biopsies. This resulted in a diagnosis of M2 instead. of 
M1 in four out of seven cases of M1 [see Table 21]. 
Table 21: Concordance between plastic embedded bone marrow biopsy [8MB] 
sections and marrow aspirate [BMA] 
[Total 15 cases] 
MO M1 M2 M3 M4 MS M6 M7 ~M~ 
Total 
------------------------------------------------------------------------------- - -------
MO 1 1 
-------------------------------------------------------------------------------- ... -------M1 3 4 7 
------------------------------------------------------------------------t-------
M2 3 3 
--------------------------------------------------------------------------------· -------M3 2 2 
--------------------------------------------------------------------------------- -------M4 1 1 
---------------------------------------- .-------------------------------------- - -------MS O 0 
--------------------------------------------------------------------------------- -------M6 1 1 
. --------------------------------------------------------------------------------- -------M7 
[8MB] 
Total 
Abbreviations: 
3 7 
BMB - bone marrow biopsy 
BMA - bone marrow aspirate 
2 
0 0 
1 0 0 15 
.. 
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CHAPTER FIVE 
DISCUSSION 
The classification system of MOS and AL most widely used today is that devised by 
a collaborating group of French-American-British haematologists. In order to apply the 
French-American-British [FAB] criteria for the diagnosis of MOS and ANLL [originally 
designed for blood films and marrow aspirates] to diagnoses based on marrow 
biopsies, five conditions need to be fulfilled in bone marrow biopsies: 
r--~----~------------------------------------------------------------------------~ 
: 1. Recognition of dysplastic features in all three cell lines. : 
~--~------------------------------------------------------------------------------~ 
: 2. Quantitative evaluation of the percentage of blasts. : 
~--~------------------------------------------------------------------------------~ 
: 3. Quantitative evaluation of the number of sideroblasts. I 
~--~------------------------------------------------------------------------------~ 
: 4. Knowledge of the peripheral blood morphology with blast and : 
: monocyte counts. : 
~--~------------------------------------------------------------------------------~ 5. Qualitative and quantitative evaluation of the markers used in defining 
the subclasses of ANLL: 
Myeloperoxidase 
Naphthol-AS chloroacetate esterase [CAE] 
Alpha-naphthyl butyrate esterase [ANBE] I 
I 
I 
I 
Periodic acid Schiff [PAS] 
lmmunophenotyping l 
--~-----------~-----------------------------------------------------------------~ 
All five criteria will be fulfilled by the use of thin GMA-embedded sections, which give 
superior preservation of cytological details as well as allowing the application of 
cytochemical and immunophenotyping techniques. 
A unique feature in this study was the use of a -20 °c bath with embedding moulds 
placed at the top [Fig.1 O], which enabled very effective cooling of the polymerization 
process; this tended to exceed the boiling point if it was done at room temperature. 
The boiling point of the embedding mixture was further decreased by application of 
a vacuum, which was found to be essential for uniform infiltration of the marrow core. 
All published studies by Henderson (14), Moosavi (21), Islam (33) and Casey (99) 
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reported polymerization at room temperature or 4 °C, which was found unsuitable in 
this study as it was complicated by boiling with the resultant formation of air bubbles. 
The fixation and dehydration of marrow cores using a 50% concentration of acetone 
at -20 °c gave good morphologic definition of cells, and processing the biopsies in the 
cold [-20 °C] enabled excellent preservation of several enzymes useful in diagnosing 
various haematological malignancies. 
Another major advantage of embedding marrow in glycol methacrylate is the relatively 
short processing time [ of 6-8 hours as compared to 36 hours with paraffin embedding] 
which allows sections to be assessed on the same day as the biopsy is taken. 
It is noteworthy that GMA processing of marrow biopsies does not require any special 
equipment except a microtome, and cutting tissue into 2 microns sections can be done 
easily, even by an untrained person. 
The cost of embedding one marrow core in GMA is about twice that of paraffin, but 
using this medium is quicker, less complicated, and gives superior morphological 
details. 
ARCHITECTURAL DISTORTION 
A distortion of topographic distribution of haemopoietic cells in marrow cavity is found 
in several diseases, but typically in MOS. Distortion of normal marrow architecture was 
observed in 8 MOS cases, whereas abnormal localization of immature precursors 
[ALIP] [Fig 6] was noticed on biopsy in four cases with two already being diagnosed 
as ANLL on GMA sections. Tricot et al (1) pointed out the significance of the presence 
of the abnormal localization of immature precursors [ALIP] which they reported in 28 
out of 40 patients. ALIP was also reported in 17 out of 28 MOS patients by Delacretaz 
et al (28). 
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This feature [together with cellularity] is reported to have not only diagnostic but also 
prognostic significance (28,32). This means that in some patients [particularly in the 
MOS group] the FAS category may change after assessment of marrow cavity 
architectural distortion, and the patient may have a less favourable prognosis, or even 
overt acute leukaemia (34). 
CELLULAR ITV 
In general it is believed that bone marrow aspirates do not accurately reflect the 
marrow cellularity. (13,34) Tricot et al (1) suggested that the diagnosis of MOS could 
not be established on bone marrow smears alone, as these may not be representative. 
Similarities in cellularity between aspirates and biopsies were observed in 8 out of 13 
MOS cases. Cellularity tends to be higher in biopsies than in aspirates, and this 
agrees with the study published by De Wolf-Peeters et al (30) who found hypercellular 
marrow in 80% of biopsies, with an increase in reticulin fibrosis in 65% of MOS patients. 
Paguliuca et al ( 42) reported the presence of marked marrow fibrosis in 10 cases of 
MOS [median age 66 years]. showing trilineage dysplasia with increased 
megakaryopoiesis and marked reticulin fibrosis. Marked reticulin fibrosis associated 
with an increased number of megakaryocytes is most likely a result of production [by 
the latter] of potent polypeptide growth factors, such as platelet-derived growth factor 
[POGF] which plays a major role in reticulin formation (2, 16, 17,109,110). On the 
contrary, in ANLL patients, megakaryocytes are usually grossly decreased or even 
absent. 
It is reported (106,111) that older patients have a tendency to have greater amounts 
of reticulin which may explain partially why there were significant differences in 
cellularity and number of blasts between marrow biopsy and marrow smears in MOS 
patients [median age 68 years]. Discrepancies between histological and cytological 
assessment of cellularity in MOS may also result from the patchy distribution of 
haemopoietic tissue. 
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The assessment of cellularity in ANLL group in this study showed considerable 
similarities in all but two cases and in the discrepant cases, differences were small. 
Such considerable agreement in cellularity and number of blasts in the ANLL group 
can be related to a lower median age of ANLL patients [44 years], than of the MOS 
group [68 years]. This observation is similar to findings reported by Islam et al (31) 
who found that assessment of cellularity by aspirate and biopsy were comparable in 
ANLL. 
In summary, cellularity was found to be concordant between aspirate and biopsy in the .• 
ANLL group but was significantly discordant in MOS individuals, while no aspirate was 
obtained in two patients. Thus, in the latter category, biopsy material is essential for 
diagnosis. 
BLASTS 
Quantification of marrow blasts represents the most important step in the application 
of the FAB classification of myelodysplastic syndromes and acute leukaemias (7, 8, 9, 
10, 11, 23, 29, 40, 76). However, a true estimate of the percentage of blasts in marrow 
smears can be difficult, because blasts are often in clusters in areas not reached by 
aspiration or are retained by the reticulin network. Islam et al (31) reported that the 
proportion of haemopoietic cells was more accurately assessed in the sections of 
marrow cores than the aspirate. In four out of 34 patients, granulocytic precursors 
were not seen in the marrow aspirate but were easily identified in the biopsies (31). 
This problem can be overcome by trephine biopsy, which appears to be more 
accurate for quantification of the blast population, although identification of blasts in 
GMA sections is not always easy and requires practice and sometimes application of 
special stains. 
In MOS patients biopsy tended to show a higher number of blasts and also detected 
blast clusters. This resulted in a change of FAB diagnosis made on aspirate in six 
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cases of MOS - two patients were diagnosed on marrow biopsy as ANLL against 
RAES-t and RA, and 4 were diagnosed on sections as RAES against RA, RARS, and 
CMML. Such changes in diagnosis are significant as they have both therapeutic and 
prognostic implications. This was probably related to the increased reticulum and also 
to the patchy distribution of blasts in the marrow in MOS. 
Discrepancies between aspirate and biopsy in the number of blasts and cellularity was 
marginal in the ANLL group, with cytology being more sensitive in the detection of 
blasts. Maturation of granulocytic precursors was more pronounced in the biopsy t~an 
on the cytology, which resulted in a diagnosis of M2 instead of M1 in 4 cases. 
Thus, biopsy appears to be more accurate in the assessment of haemopoietic cell 
maturation, quantification of blasts in the MOS group, and is invaluable for diagnosis 
in cases were no marrow aspirate can be obtained. 
DVSPLASTIC FEATURES 
The detection of dysplastic features in peripheral blood and bone marrow in MOS 
plays a significant diagnostic role in the FAS classification (2, 4, 9, 32, 49, 70}. 
The most frequent abnormality observed in marrow biopsies was dysmegakaryopoiesis 
followed by dysmyelopoiesis and dyserythropoiesis [Table 1 O] . 
On GMA-embedded marrow sections dyserythropoiesis [Fig.5] was observed in all 13 
cases of MOS, while on aspirate it was not observed in 4 patients [Table 1 O]. 
Oysgranulopoiesis was more frequently observed on marrow sections than on aspirate 
[Table 1 O]. Use of cytochemistry enabled the detection of cytoplasmic dysplasia 
[Fig.13], and may play a significant supportive role in the differentiation of cells on 
marrow sections. 
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Two patients diagnosed on aspiration as MOS had more than 30% blasts on marrow 
sections, and with more than 3% positivity for myeloperoxidase and CAE in blasts, 
could be classified as ANLL. Pseudo Pelgar-Huet anomalies [Fig.6] are reported only 
in the clonal diseases (for example MOS, ANLL, CML)(48). This abnormality was 
observed in 1 O out of 13 cases on the marrow sections and also in the peripheral 
blood. These findings are similar to those of Ginnai et al ( 48) who reported that the 
presence of pseudo Pelgar-Huet anomalies and micromegakaryocytes would enable 
one to distinguish MOS from other haematological disorders and from normal subjects. 
Micromegakaryocytes [Fig.7] were observed in all 13 cases on the marrow sections 
[Table 1 O]. Several studies have shown that dysmegakaryopoiesis was frequently 
present in MOS, and in particular the presence of micromegakaryocytes was limited 
to MOS and ANLL (1, 28, 29, 32, 34). 
The number of peripheral blood blasts and monocytes must also be taken into 
account in an MOS classification, and in this study four CMML cases were diagnosed 
mainly on monocyte counts in peripheral blood. Two CMML cases were reclassified 
on marrow sections as RAEB as a result of an increased number of blasts [5%-20%] 
in the marrow sections. 
In summary, dysplastic features were more readily observed on biopsies than on 
aspirate, and enabled the use of cytochemistry which markedly improved diagnostic 
accuracy. 
SPECIAL STAINS 
Careful processing of the specimens at -20 °c permitted the performance of 
cytochemical and immunophenotyping studies which are used in the differentiation of 
acute myeloid and lymphoid leukaemias. 
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Myeloperoxidase in this study was positive [more than 3% of blasts positive] on 
marrow sections in seven cases of ANLL. Four cases were negative, but strong 
positivity for CAE still enabled the diagnosis of ANLL to be made. In two cases of M3, 
both myeloperoxidase and CAE were strongly positive, with CAE showing numerous 
Auer's rods in one of the cases [Fig.25]. 
In the two subjects negative for MPO and CAE cases the diagnosis had to be 
supported by myeloid monoclonal antibodies [anti-MPO, CD 13, CD33] [Fig.26, Fig.27, 
Fig.28]. 
Two cases of M4 ANLL did not show expected positivity for ANBE on marrow sections, 
showing only positivity for myeloperoxidase and CAE. In these individuals the 
diagnosis of M4 was supported by a significant morphologic monocytic component, 
easily recognizable on GMA marrow sections [Fig.3], and also by abnormal looking 
monocytes in the peripheral blood which accounted for more than 16 x1 o9 /L of all 
cells [case No.4], still making the diagnosis of M4, despite the negative ANBE stain in 
marrow sections. 
A high level of serum lysosyme would be another feature supportive of the diagnosis 
(8,11). In a second case of M4-M4E [case no. 14], GMA-embedded sections showed 
20% eosinophils with positivity for CAE [Fig.8]. 
Sudan Black 8 cytochemistry is unsuitable for GMA embedded tissues as application 
of reagents dissolves the sections. 
The staining preparation routinely used to demonstrate reticulin fibre network, Gomori's 
stain, did not appear to be as positive in GMA sections as on paraffin, but it was found 
that alkaline phosphatase stains could be used as surrogate tests to detect reticulum 
increase (22) [Fig.20]. 
The enzyme acid phosphatase is a valuable marker for lymphoid malignancies and 
helps to distinguish different types of acute and chronic lymphoproliferative 
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disorders. It is important in characterizing T and non-TALL (2,70). 
Positivity for acid phosphatase was found to be present only in the reticulum cells of 
some cases of MOS and ANLL [Fig.17] and was very strongly positive in osteoclasts 
[Fig.16]. 
The PAS stain was valuable in showing block positivity in RAEB-t transforming to 
erythroleukaemia [Fig.15]. 
Prussian blue staining allowed for iron store estimation [Fig.21] and the detection of 
ring and pathological sideroblasts [Fig.22]. 
GMA processed marrow also enabled the detection of stainable iron at the surface of 
undecalcified trabecular bone, [Fig.23] which was observed in some large studies in 
2.8% of marrow biopsies (112). Primary or secondary haemochromatosis appear to 
be the conditions most likely to be associated with this phenomenon, but it was also 
noted in malignant conditions (112). 
In summary, cytochemistry is generally less important in the assessment of MOS 
patients, except perhaps alkaline phosphatase for assessment of reticulum. The use 
of myeloid markers did, however, allow better recognition in some cases of MOS, and 
uneven cytoplasmic staining was an indication of the dysplastic maturation of myeloid 
precursors [Fig.13]. 
Cytochemistry, because of cold processing, excellently preserved enzymatic activity 
in GMA sections, played a crucial role in the diagnosis and differentiation of AL, also 
allowing the diagnosis of ANLL in one case, in which no aspirate could be obtained. 
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IMMUNOPHENOTYPING 
lmmunophenotyping was the most difficult part of this study, requiring very laborious 
and careful processing. Theoretically, plastic embedding should be superior to frozen 
and paraffin sections for immunophenotyping through better antigenic and 
morphologic preservation. In practice, water-soluble plastics like GMA apparently bind 
to the amino-terminal portions of proteins during polymerization and hence mask 
antigenic epitopes (13,99). 
Casey et al {99) reported that the addition of 5% methyl benzoate to the GMA 
monomer infiltration solution protects antigens from being masked by GMA during 
polymerization but preserves antigens only in acetone fixed tissues. 
He also reported that storage of marrow blocks or sections at -20 °c even for several 
months, did not alter immunoreactivity. This was also our experience. 
lmmunophenotyping was performed by the double-conjugated indirect peroxidase 
method. The alkaline phosphatase-antialkaline phosphatase [APAAP] technique was 
also attempted but did not show the positivity expected in GMA embedded marrow 
sections, although Casey et al {99) reported satisfactory results using this method. As 
GMA marrow sections have preserved endogenous peroxidase activity, the APAAP 
method could be most suitable for bone marrow immunophenotyping as no blocking 
procedure of endogenous peroxidase is required {113). This is an advantage since 
blocking procedures may denature many of the antigens. The red reaction product 
of the immuno-alkaline phosphatase procedure is very easy to recognize and contrasts 
strongly with the haematoxylin counterstain {97). 
Beckstead et al (23) demonstrated reactivity of megakaryocytic antigens [GPlla, GPllb, 
and the llb-llla complex; granule membrane protein 140] in GMA embedded marrow 
sections with the use of the double-conjugated indirect peroxidase method. 
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Casey et al (99) reported that a wide variety of antigens can be detected in plastic 
sections without trypsinisation; pan-8 [CD19, CD22,], pan-T [CD7, CD3, CD5, CO2,], 
T-subsets [CD4, CD8, CD1, CD25] as well as surface immunoglobulin, markers for 
myeloid antigens [CD13, CD33,] and monocytic antigens [CD14, CD15]. By using this 
method we were able to show reactivity with anti-MPO, CD13 and CD33, with the last 
two antibodies reacting only after modification of the method by incubating overnight 
with primary antibody. In our study we could not reproduce the reactivity of antigens 
with monocytic antibodies as reported by Casey et al despite very stringent application 
of the method. 
The MPO antibody which allows recognition of myeloperoxidase positive cells was 
found to be reliable and most sensitive in the identification of cells of myeloid origin 
[Fig.26]. CD13 and CD33 positivity was achieved only after overnight incubation at 4 
0 c with the primary antibody, which considerably extends processing time [Fig.27, 28]. 
Together these three monoclonal antibodies allow for diagnosis of more than 95% of 
ANLL, (88, 91) which make them very valuable in this setting, particularly in cases 
where no aspirate can be obtained. 
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CHAPTER SIX 
SUMMARY 
In the MOS group of patients, final morphological agreement in diagnosis was 
observed in only 7 out of 13 cases, with significant changes of diagnosis on marrow 
sections in 6 patients, implying that biopsy, with its more accurate blast count, is more 
precise and accurate in the classification of MOS, and also allows a diagnosis to be 
made in those cases in which marrow aspirates cannot be obtained. 
In the ANLL group, combined histological, cytological and immunological marrow 
aspirate classification was in agreement in 11 out of 15 cases of ANLL, with marrow 
sections showing more accurately the maturation present in myeloid cells, resulting in 
a diagnosis of M2 instead of M1 in 4 ANLL cases. 
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CHAPTER SEVEN 
CONCLUSIONS 
This study showed that the FAB Cooperative Group criteria, originally designed for 
marrow aspirates, can be applied to thin GMA embedded marrow biopsies and can 
allow the diagnosis of MOS or ANLL in cases where aspiration is inadequate. These 
criteria, when applied to marrow sections, allow for more precise and accurate 
differentiation of leukaemic sub~types. 
The maximal accuracy can, however, be obtained only by analysis of morphological, 
cytochemical, immunological, karyotypic and, in some cases, ultrastructural 
investigations. 
Another major advantage of embedding marrow in glycol methacrylate is the relatively 
short processing time of 6-8 hours [ as compared to 36 hours with paraffin embedding] 
which allows sections to be assessed on the same day as the biopsy is taken. 
The simplicity, short processing time, reproducibility, excellent morphology, 
cytochemical and immunophenotyping staining makes this method highly suitable for 
routine work in the haematology laboratory . 
.. 
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